Document:

EX-10.22

 Exhibit 10.22 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE HORIZON THERAPEUTICS PLC HAS DETERMINED
THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO HORIZON THERAPEUTICS PLC IF PUBLICLY DISCLOSED. 

SUPPLY AGREEMENT 
 Dated:
August 3, 2015 
 between 

CREALTA Pharmaceuticals LLC 
 and

 NOF CORPORATION 

  
 1 

 SUPPLY AGREEMENT 

This SUPPLY AGREEMENT (“Agreement”) is made and entered into on the 3rd day of August, 2015 by
and between CREALTA Pharmaceuticals LLC., a Delaware limited liability company with offices at 150 S. Saunders Rd., Suite 130, Lake Forest, IL 60045, U.S.A. (“CREALTA”), and NOF CORPORATION, a corporation duly organized under the laws of
Japan, located at 20-3, Ebisu 4-chome, Shibuya-ku, Tokyo, 150-6019, Japan
(“NOF”), 
 WITNESSETH : 
 WHEREAS
CREALTA is a specialty pharmaceutical company undertaking the research, development, manufacturing, and marketing of therapeutic products for the treatment of diseases; 

WHEREAS NOF carries on the business of manufacture and supply of pharmaceutical materials, and has certain proprietary technology of the Activated PEG (as
defined below); and 
 WHEREAS NOF is willing to supply the Activated PEG to CREALTA and CREALTA is willing to accept and purchase such supply from NOF on
the terms and conditions contained herein. 
 NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained in this Agreement
the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
  

	1.1	 “Activated PEG” shall mean [***] further details of which are set out in the Specification (as
defined below). 

  

	1.2	 “Affiliate” shall mean a company that, directly or indirectly, through one or more intermediates,
controls, is controlled by, or is under common control with the company specified. For the purpose of this definition, control shall mean the direct or indirect ownership of more than fifty percent (50%) or, if not more than fifty percent (50%), the
maximum percentage as allowed by applicable law of (i) the stock of shares entitled to vote for the election of directors or (ii) ownership interest. 

 

	1.3	 “BLA” shall mean a regulatory application filed with a governmental agency in a country or a group of
countries for the purpose of lawfully marketing, selling, distributing, importing, exporting, manufacturing, developing or using a therapeutic or prophylactic product for the treatment or prevention of a disease or physical condition; A BLA shall
include, without limitation, a Product License Application or Marketing Authorization in the European Union, and a Biologics License Application or a New Drug Application in the United States. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 2 

	1.4	 “cGMP” shall mean the current principles and guidelines of good manufacturing practice and general
biologics product standards as contained in US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610) in relation to the production of pharmaceutical intermediates and active pharmaceutical ingredients, as interpreted by ICH
Harmonized Tripartite Guideline, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Q7A, as shown in detail on the Quality Agreement as each may be amended from time to time, all subject to any arrangements, additions or
clarifications agreed from time to time between the Parties in the Quality Agreement. In the event that there exists any difference or discrepancy between the Quality Agreement on one hand and above principles, guidelines and standards on the other,
the Quality Agreement shall prevail. 

  

	1.5	 “Effective Date” shall mean the date of this Agreement first referenced above. 

 

	1.6	 “FDA” shall mean the United States Food and Drug Administration. 

 

	1.7	 “Force Majeure” shall mean any unforeseeable occurrence beyond the reasonable control of a Party that
prevents the performance by that Party of any of its obligations hereunder arising from or attributable to acts, events, non-happenings, omissions, accidents or any other similar cause which is unforeseeable
and beyond the reasonable control of such Party. 

  

	1.8	 “Legal Requirements” shall mean (i) any present and future national, state, local or similar
laws (whether under statute, rule, regulation or otherwise) and (ii) requirements under permits, orders, decrees, judgments or directives, and requirements of applicable Regulatory Agencies (including, without limitation, cGMP) (with respect to
each of the foregoing, as amended or revised from time to time). 

  

	1.9	 “Party” shall mean either CREALTA or NOF, as is appropriate in the given context and the plural shall
mean both CREALTA and NOF. 

  

	1.10	 “Quality Agreement” shall mean the list of responsibilities of the Parties relating to cGMP
activities, a copy of which is attached hereto as Exhibit D and incorporated herein by reference. The Quality Agreement shall be updated from time to time by mutual written agreement of the Parties. 

 

	1.11	 “Quarterly” shall mean a period of three (3) consecutive months commencing on 1 January,
1 April, 1 July, and 1 October in each calendar year during the Term of this Agreement. 

  

	1.12	 “Regulatory Agency” shall mean with respect to the United States, the FDA, or, in the case of a
country in the Territory other than the United States, such other appropriate regulatory agency with similar responsibilities. 

  

	1.13	 “CREALTA Products” shall mean [***]. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 3 

	1.14	 “Specification” shall mean the agreed upon procedures, requirements, standards and other items set
forth in the attached Exhibit A which is incorporated herein by reference. Exhibit A shall be updated from time to time by mutual written agreement of the Parties hereto. 

 

	1.15	 “Third Party” shall mean any person or party other than CREALTA, NOF and their respective Affiliates.

  

	1.16	 “Year” shall mean the twelve (12) month period commencing on the Effective Date and any
subsequent anniversary of the Effective Date. 

  

	1.17	 References to the singular shall be deemed to include the plural and vice versa. 

 

	1.18	 References to statutory provisions shall include the same as amended or
re-enacted from time to time, whether before or after the date hereof. 

 ARTICLE 2

 COMMENCEMENT OF SUPPLY 
  

	2.1	 Intentionally Blank. 

 

	2.2	 Commencement of Supply. The commencement of supply of Activated PEG pursuant to this Agreement shall not
occur until such a time as CREALTA shall have submitted to NOF a Forecast (as defined below), where such Forecast shall include a Firm Order (as defined below) which shall not require delivery of any Activated PEG in less than [***] from the date of
the submission of the Firm Forecast (hereafter the, “Supply Commencement Date”). 

 ARTICLE 3 

MANUFACTURE AND SUPPLY 
  

	3.1	 Manufacture and Supply. In furtherance of the manufacturing CREALTA Products to be used as a drug or
device for the treatment of [***] or other diseases and conditions involving [***] (hereinafter, the “Field”), NOF agrees to manufacture and supply the Activated PEG to CREALTA or CREALTA’s designated agent in accordance with the
terms of this Agreement and CREALTA agrees not to use, transfer or otherwise dispose of the Activated PEG for any other purpose. NOF further confirms that all orders placed by CREALTA for the Activated PEG will be manufactured under cGMP. The
parties agree that the nominal batch size for the production of Activated PEG pursuant to this Agreement shall be approximately [***]; CREALTA shall provide Forecasts (as hereinafter defined) for Activated PEG and place orders in quantities no less
than [***] per shipment. 

  

	3.2	 Forecasting and Orders. CREALTA shall forecast and order the Activated PEG as follows:

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 4 

	 	(a)	 Not less than [***] prior to the Supply Commencement Date and Quarterly thereafter, CREALTA shall provide to
NOF a rolling [***] forecast, starting from the Supply Commencement Date, of its expected quarterly requirements for the Activated PEG (“Forecast”), the first [***] of which shall be binding (a “Firm Forecast”) and the last [***]
of which shall be non-binding. The Forecast will include the required delivery dates and delivery locations for the Activated PEG, such delivery dates to be no sooner than [***] days from the date of
transmission of the Forecast to NOF. The Forecast will be updated Quarterly by CREALTA. The non-binding portions of the Forecast, the last [***], may be modified by CREALTA plus or minus [***]% upon each
quarter becoming a Firm Forecast provided, however, that the total amount of the non-binding portions of the Forecast may not increase or decrease by [***], plus or minus, within such non-binding [***] period unless the parties shall agree otherwise. 

  

	 	(b)	 Within [***] days of receipt of the Forecast and each quarterly updated Forecast, NOF shall reply in writing
whether it will agree to meet the required Forecast and delivery dates. If, despite the use of best commercial efforts, NOF projects that it is unable to agree to the Forecast or updated Forecast and the delivery dates set forth therein, the Parties
shall use their reasonable efforts to agree to a revised Forecast and delivery dates. Provided, however, that NOF shall not modify the delivery dates for any Firm Forecast previously accepted by NOF unless there has been an increase or decrease to
the quantity specified by CREALTA in the updated Forecast. Additionally, the parties agree that time is of the essence in resolving any dispute arising hereunder and shall use their best efforts to agree upon a revised Forecast as soon as possible.

  

	 	(c)	 CREALTA shall place binding written purchase orders setting forth delivery dates of each quarter for the
Activated PEG based on the Firm Forecast and updated Firm Forecasts at least [***] before the agreed upon delivery date (“Firm Order”). 

  

	3.3	 Delivery. NOF shall deliver such quantities of Activated PEG to CREALTA as agreed upon by the parties in
accordance with the terms of Section 3.2 herein; such quantities shall be delivered on or before the dates agreed upon by the Parties in accordance with Section 3.2. Promptly after shipment of the Activated PEG to CREALTA, NOF shall notify
shipping information to CREALTA in writing by invoice or other documentation. Delivery shall be [***] (Incoterms 2000) or to such other location as may be directed by CREALTA in the applicable Firm Order. NOF shall ship the Activated PEG, properly
packaged and labeled in accordance with the Specifications, to CREALTA or CREALTA’s designee. If the Activated PEG is not delivered in accordance with this Agreement, both Parties agree to consult with each other to rectify the non-delivery within [***] days after receiving request for consultation from either Party. 

  

	3.4	 Delivery Documentation. Prior to shipping the Activated PEG as set forth in Section 3.3, NOF shall
send to CREALTA a Certificate of Analysis (“C of A”) certifying the conformance of the 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 5 

	 	
Activated PEG to the Specification and with all warranties set forth in ARTICLE 4, which C of A will be signed by the head of the Quality Assurance unit at NOF’s manufacturing facility. The
C of A shall be sent to the attention of CREALTA’s designated party from time to time prior to the release of the shipment by NOF. Provided, however, that CREALTA shall refer to and state the above requirements on every Firm Orders. The
original C of A shall accompany the shipment of the Activated PEG. NOF shall have the responsibility of authorizing the release of any Activated PEG ordered and prior to shipment of the Activated PEG NOF shall supply the C of A to CREALTA as set
forth above. 

  

	3.5	 Minimum Purchase There are no minimum yearly purchase requirements. 

 

	3.6	 Intentionally Blank. 

 

	3.7	 Supply Failure. In the event that NOF is unable to supply at least [***] percent ([***]%) of
CREALTA’s Firm Forecast quantities (hereinafter, a “Supply Failure”), then both parties agree to meet and use their best efforts to solve such Supply Failure. 

 

	3.8	 Exclusivity of Purchase and Supply. CREALTA agrees that for CREALTA Products, it shall procure Activated
PEG from NOF on an exclusive basis and shall not purchase or otherwise procure Activated PEG from any Third Party during the Term of the Agreement; provided, however, that in the event a Supply Failure shall occur, CREALTA shall have the right, but
not the obligation, to obtain such quantities of Activated PEG as it may require for such a period of time until the Supply Failure has been remedied to CREALTA’s reasonable satisfaction. 

ARTICLE 4 
 QUALITY 

If there is any inconsistency between any provision of this ARTICLE 4 and that of the Quality Agreement, the latter shall prevail. 

 

	4.1	 Quality Control. 

 

	 	(a)	 NOF shall perform, or cause to be performed, quality control tests and procedures in accordance with the
Quality Agreement to verify that each batch of the Activated PEG conforms to the Specification. 

  

	 	(b)	 NOF will make available to CREALTA any other relevant information, documents and/or data pertaining to the
manufacturing and testing of the Activated PEG. In addition, if the Activated PEG deviates from the Specification, the variance and non-conformance data and records shall promptly be reported in writing to
CREALTA. 

  

	4.2	 Rejection. Within [***] days following the day on which CREALTA or CREALTA’s designated agent, as
the case may be, receives delivery of the Activated PEG or the C of A (whichever is the later), CREALTA shall have the right to reject the Activated PEG batch (or part 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 6 

	 	
thereof) which fails to conform to the applicable Specification or otherwise fails to conform to warranties given by NOF set forth in ARTICLE 5, provided that this Section 4.2 shall not
apply if the failure to conform to applicable Specification is due to any action or inaction on the part of CREALTA. Any such rejection shall be made by written notice to NOF specifying the manner in which all or part of such batch fails to meet the
foregoing requirements. 

  

	4.3	 Failure to Conform. If any batch of the Activated PEG fails to conform to the Specification or otherwise
fails to conform to the warranties set forth in ARTICLE 5 for any reason, CREALTA shall, at NOF’s election (a) return such batch to NOF at NOF’s direction and expense within [***] days following the date of written notice of rejection
by CREALTA pursuant to Section 4.2, or (b) destroy such batch and provide to NOF certification of such destruction in a form reasonably acceptable to both NOF and CREALTA. 

 

	4.4	 Refund. Payment for any Activated PEG shall not be deemed acceptance if at a later date such batch is
rejected pursuant to Section 4.2 or fails to conform pursuant to Section 4.3, and NOF shall refund the price of all rejected Activated PEG to CREALTA within [***] days of the rejection of the Activated PEG. 

 

	4.5	 Samples and Records. NOF shall prepare and keep batch records and shall retain samples, properly stored
in accordance with the Quality Agreement, from each batch of the Activated PEG manufactured by NOF. NOF shall comply with cGMP in retaining batch records and samples. NOF shall prepare and keep complete and accurate records of all the Activated PEG
manufactured for CREALTA consistent with cGMP requirement. Subject to the confidentiality obligations set out in ARTICLE 6, CREALTA or its designee shall have access to all such records and samples on reasonable notice and during normal business
hours. In the event CREALTA requires records or documentation, other than those to be maintained by NOF as described above, to file applications to a Regulatory Authority, NOF will assist CREALTA in the preparation of such records and documentation
to the extent requested by CREALTA and at CREALTA’s expense. 

  

	4.6	 Presence at Facility. CREALTA shall have the right, from time to time, to assign a reasonable number of
its employees or representatives to visit NOF’s manufacturing facility and any other relevant location (e.g. warehouse) for [***] days per Year (or such other period as may be agreed by the Parties in the event that any material non-compliance with the terms of this Agreement or in the manufacture of the Activated PEG is discovered) in order to inspect, discuss and review the activities performed by NOF under this Agreement and to verify
NOF’s compliance with the warranties in ARTICLE 5 with respect to the Activated PEG. The presence of CREALTA’s employees or representatives shall in no way relieve NOF of any of its obligations under this Agreement. 

ARTICLE 5 
 WARRANTIES AND
LIABILITY 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 7 

	5.1	 Warranties. NOF hereby covenants, represents and warrants to CREALTA that: 

 

	 	(a)	 On the date of shipment from Japan of the Activated PEG sold by NOF to CREALTA hereunder and until acceptance
by CREALTA pursuant to the terms of this Agreement, the subject Activated PEG will comply with all requirements of this Agreement and shall comply with the Specification and conform to the information shown on the C of A and reports provided for the
particular batch according to Section 3.4 hereof; additionally, such Activated PEG shall have not less than [***] expiry dating on the date of shipment from NOF to CREALTA or CREALTA’s designee. 

 

	 	(b)	 To the best knowledge of NOF, no technology used in the manufacture of Activated PEG is the subject of any
third party intellectual property rights but NOF shall not warrant that the Activated PEG and the technology shall be free from any claims of infringement upon patents and any other intellectual property rights of any third party.

  

	 	(c)	 At the time that title to the subject shipment of Activated PEG passes to CREALTA pursuant to the terms of this
Agreement, NOF shall have good title thereto which shall pass to CREALTA free and clear of any and all liens, encumbrances, or any other possessory or financial interests. 

 

	 	(d)	 Permits. NOF has and shall maintain all necessary licenses, permits and registrations for the
manufacture of the Activated PEG and supply of the same hereunder. 

  

	5.2	 Consequential Damages. In no event shall either Party be liable, whether under this Agreement or
otherwise, for any indirect or consequential damages (including without limitation loss of profits, loss of opportunity, interruption of business, loss of goodwill, and the costs of cover), suffered by the other Party and arising out of any breach
of this Agreement or out of any dispute relating thereto. 

  

	5.3	 Indemnity by CREALTA. CREALTA shall defend, indemnify and hold NOF, NOF’s Affiliates and their
directors, officers, employees and agents (collectively “NOF INDEMNITEES”) harmless for all losses, liabilities, damages and expenses (including reasonable attorney’s fees and costs) resulting from all claims, demands, actions and
other proceedings by any third party to the extent arising from: (a) the breach of any representation, warranty or covenant of CREALTA contained in this Agreement; (b) the research, development, manufacturing, commercialization or
marketing of CREALTA Products; or (c) the negligence, recklessness or willful misconduct of CREALTA in the performance of its obligations under this Agreement. 

 

	5.4	 Indemnity by NOF. NOF shall defend, indemnify and hold CREALTA, CREALTA’s Affiliates, and their
directors, officers, employees and agents (collectively “CREALTA INDEMNITEES”) harmless for all losses, liabilities, damages and expenses (including reasonable attorney’s fees and costs) resulting from all claims, demands, actions and
other proceedings by any third party to the extent arising from: (a) the breach of any representation, warranty or covenant of NOF 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 8 

	 	
contained in this Agreement; or (b) the negligence, recklessness or willful misconduct of NOF in the performance of its obligations under this Agreement. 

 

	5.5	 Exclusion from CREALTA Indemnity. The Parties agree that the Activated PEG supplied hereunder will be
used solely for the purpose of manufacturing CREALTA Products. The Parties further agree that the indemnity given by CREALTA in relation to CREALTA Products in Section 5.3(b) above shall not apply if the claim, demand, action or other
proceeding can reasonably be shown by CREALTA to be solely due to NOF’s fault in the manufacture of the Activated PEG to CREALTA under this Agreement. 

  

	5.6	 Indemnification Procedures. A Party seeking indemnification under this ARTICLE 5 (the “INDEMNIFIED
PARTY”) shall give prompt notice of the claim to the other Party (the “INDEMNIFYING PARTY”) and, provided that the INDEMNIFYING PARTY is not contesting the indemnity obligation, shall permit the INDEMNIFYING PARTY to control any
litigation relating to such claim and disposition of any claim as the settlement or disposition relates to the INDEMNIFIED PARTY being indemnified under this ARTICLE 5, and the INDEMNIFYING PARTY shall not settle or otherwise resolve any claim
without prior notice to, and the consent of, the INDEMNIFIED PARTY, if such settlement involves any remedy other than the payment of money by the INDEMNIFYING PARTY, such consent not to be unreasonably withheld, delayed or denied. The INDEMNIFIED
PARTY shall cooperate with the INDEMNIFYING PARTY in its defense of any claim for which indemnification is sought under this ARTICLE 5, at the INDEMNIFYING PARTY’s expense. 

 

	5.7	 Insurance. Each Party, at its own expense, shall maintain (with a reputable insurer or through
self-insurance) comprehensive general liability insurance, including product liability insurance, in the amount of [***] US dollars ($[***]) per occurrence. Each Party shall maintain such insurance from the Effective Date, and shall from time to
time provide copies of certificates of such insurance to the other Party upon its request. 

  

	5.8	 Limitation on Liability. Notwithstanding the foregoing provisions to the contrary, both Parties agree
that NOF’s liability arising from or in connection with any claim under this Agreement including Section 5.5 above and/or relative to the Activated PEG shall be limited to [***] US dollars ($[***]) for any particular Year in which such
claim is made against NOF. 

  

	5.9	 Each Party warrants that: 

 

	 	(a)	 It has full corporate right, power and authority to enter into this Agreement and to perform its respective
obligations under this Agreement; 

  

	 	(b)	 The execution and delivery of this Agreement by such Party and the performance of such Party’s obligations
hereunder (a) do not conflict with or violate any requirement of applicable laws or regulations existing as of the effective date and applicable to such Party and (b) do not conflict with, violate, breach or constitute a default under, and
are not 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 9 

	 	
prohibited or materially restricted by, any contractual obligations of such Party or any of its Affiliates existing as of the effective date; and 

 

	 	(c)	 Such party is duly authorized, by all requisite corporate action, to execute and deliver this Agreement and the
execution, delivery and performance of this Agreement by such Party does not require any shareholder action or approval or the approval or consent of any Third Party, and the person executing this Agreement on behalf of such Party is duly authorized
to do so by all requisite corporate action. 

  

	5.10	 No Warranty. NOF gives no warranties in respect of the Activated PEG other than as expressly provided in
this ARTICLE 5. 

 ARTICLE 6 

CONFIDENTIALITY 
  

	6.1	 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed to in
writing by the Parties, the Parties agree that, for the Term of the Agreement and for [***] Years thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose, and shall not use for any purpose other than as
provided in this Agreement, all confidential or proprietary information, data, documents or other materials supplied by the other Party under this Agreement and marked or otherwise identified as “Confidential” or, by necessary implication,
considered confidential, including information derived from a site visit to NOF’s facility by CREALTA (hereinafter “Confidential Information”). Each Party shall use at least the same standard of care as it uses to protect its own
Confidential Information to ensure that it, its Affiliates and sublicensees (or prospective sublicensees) and all of their employees, agents, and consultants only make use of Confidential Information for purposes as expressly authorized and
contemplated by this Agreement and do not disclose or make any unauthorized use of such Confidential Information. 

  

	6.2	 Notwithstanding the foregoing, the provisions of Section 6.1 hereof shall not apply to information or
Confidential Information that the receiving Party can conclusively establish through contemporaneous written documentation: 

  

	 	(a)	 is in the public domain other than by acts of the receiving Party or its Affiliates in contravention of this
Agreement; 

  

	 	(b)	 was permitted to be disclosed by prior written consent of the other Party; 

 

	 	(c)	 has become known to the receiving Party by a Third Party, provided such Confidential Information was not
obtained by such Third Party directly or indirectly from the other Party on a confidential basis; 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 10 

	 	(d)	 prior to disclosure under this Agreement, was already in the possession of the receiving Party, its Affiliates
or sublicensees; 

  

	 	(e)	 is independently developed without use of the Confidential Information disclosed to it or its Affiliates by the
other Party; 

  

	 	(f)	 is required to be disclosed by the receiving Party to comply with any applicable law, regulation or court
order, or (in the case of CREALTA) to obtain authorisations to conduct clinical trials with, and to commercially market CREALTA Product(s), provided that the receiving Party shall provide prior notice of such disclosure to the other Party and take
reasonable and lawful actions to avoid or minimize the degree of such disclosure. 

  

	6.3	 No Confidential Information is to be disclosed or made available to an Affiliate, an agent, consultant,
licensee, potential licensee or clinical investigator who is a Third Party, unless such Third Party who is to receive or have such Confidential Information made available to it shall: 

6.3.1 be made aware of its confidential nature; and 

6.3.2 be bound by confidentiality obligations similar to those under this Agreement. 

Any breaches of the confidentiality obligations contained herein by such Affiliate or Third Party shall be considered to be breaches of such
obligations by the Party whose Affiliate is to receive or have such Confidential Information made available to it or the Party who has retained such Third Party. 
  

	6.4	 Notwithstanding the foregoing, in the event a receiving Party is required to make a disclosure of the other
Party’s Confidential Information pursuant to Section 6.2 (f), it will, to the extent permitted by law, use its best efforts to give reasonable advance notice to the other Party of such disclosure and use its best efforts to secure
confidential treatment of such information. 

  

	6.5	 This Agreement. The Parties agree that the contents of this Agreement shall be considered Confidential
Information of the Parties. The Parties will consult with each other and agree on the provisions of this Agreement to be redacted in any filings made by the Parties to the Securities and Exchange Commission or as otherwise required by law or
regulation, such agreement not to be unreasonably withheld, delayed or denied; provided further that no redactions shall be requested or required which would make any filing contemplated hereunder untruthful or incomplete or otherwise incompliant
with relevant Legal Requirements. Notwithstanding the foregoing, each Party shall have the right to disclose in confidence the material terms of this Agreement to the parties retained by such Party to perform legal, accounting or similar services
and who have a need to know such terms in order to provide such services. 

 ARTICLE 7 

PRICE AND PAYMENT 

  
 11 

	7.1	 Supply Price. The price payable by CREALTA to NOF for the Activated PEG manufactured and supplied by NOF
pursuant to CREALTA’s Firm Orders (“Supply Price”) shall be as set out in Exhibit C, and the price for each order shall be calculated based on CREALTA’s total Forecast for the Year in which the order is placed regardless of
whether NOF shall complete delivery in the Year in which it is ordered. By way of example, if CREALTA’s Forecast for a particular Year is for [***] of the Activated PEG, then orders placed during that Year will be charged at US $[***]. If at
the end of any Year actual orders purchased by CREALTA do not fall within the applicable quantity range of the original Forecast, then the Price for the Activated PEG purchased during that Year shall be adjusted to reflect that actual volume of
Activated PEG purchased by CREALTA, provided, however, if the actual amount purchased by CREALTA is less than Forecasted due to [***], then the Price for the Activated PEG purchased by CREALTA shall be based on [***]. Upon adjustment, if necessary,
either CREALTA shall pay to NOF or NOF shall credit to CREALTA, as applicable, the balance based on the said adjustment. Any amounts owing by CREALTA to NOF pursuant to this provision shall be remitted within [***] days of CREALTA’s receipt of
a reconciliation statement which sets forth in specific detail the amounts purchased by CREALTA during the Year in question; any credits owing by NOF to CREALTA shall be applied to [***]. Provided, however, that CREALTA shall pay to NOF only such
amount as corresponds with the amount of Activated PEG which is actually delivered to CREALTA or CREALTA’s designee pursuant to the terms of this Agreement. 

 

	7.2	 Supply Price Modifications. During each Year, both Parties agree to discuss in good faith and agree to
any increases or decreases in the Supply Price for the following Year which are required as a result of any demonstrable change in circumstances directly related to the manufacture and supply by NOF of the Activated PEG under this Agreement. Any
such agreed change to the Supply Price shall take effect on the first day of the following Year, provided that such agreed change to the Supply Price shall have been agreed upon no later than [***] days prior to the effective date of such change
becoming effective. Unless otherwise agreed by both Parties in writing, the Supply Price shall not be increased or decreased more than once in each Year. Anything to the contrary notwithstanding, no increase to the Supply Price for any Year shall
exceed the previous Years’ percentage increase in the United States Consumer Pricing Index. 

  

	7.3	 Payment. NOF shall invoice CREALTA for the Activated PEG upon shipment pursuant to
Section 3.3. CREALTA shall pay all undisputed amounts within [***] days of the date of receipt of a proper invoice from NOF. Without prejudice to any existing remedy NOF may have at law or contract, if CREALTA fails to pay on the due date
any amount which is payable to NOF hereunder, then CREALTA shall pay to NOF interest on such amount from the date 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 12 

	 	
payment fell due until actual payment, such interest being equal to [***] percent ([***]%) above the [***] rate fixed at the date the payment fell due. 

ARTICLE 8 
 TERM AND TERMINATION

  

	8.1	 Term. Unless earlier terminated under the provisions hereof, the term of this Agreement (“Term of
Agreement”) shall be the period of five (5) Years from the Effective Date. 

  

	8.2	 Material Breach. Either Party may terminate the Agreement forthwith by notice in writing to the other
Party if the other Party commits a material breach of this Agreement which (in the case of a breach capable of remedy) is not remedied within 30 days of the receipt by the other Party of notice identifying the breach and requiring its remedy.

  

	8.3	 Insolvency. Either Party may terminate the Agreement forthwith by notice in writing to the other Party
if the other Party ceases for any reason to carry on business or compounds with or convenes a meeting of its creditors or has a receiver or manager appointed in respect of all or any part of its assets or is the subject of an application for an
administration order or of any proposal for a voluntary arrangement or enters into liquidation (whether compulsorily or voluntarily) or undergoes any analogous act or proceedings under foreign law. 

 

	8.4	 Termination tor Convenience. Either Party may terminate this Agreement hereunder at any time without
cause, on twenty-four (24) months prior written notice to the other Party. 

  

	8.5	 Intentionally Blank. 

 

	8.6	 Effect of Termination on Additional Supply of Activated PEG. If NOF terminates this Agreement pursuant
to Section 8.4 or if CREALTA terminates this Agreement pursuant to Section 8.2 or Section 8.3, then NOF shall supply to CREALTA such amounts of Activated PEG that CREALTA shall order through the effective date of such termination in
accordance with such Forecasts and Firm Forecasts as may be submitted according to the terms of this Agreement. Furthermore, at CREALTA’s election, NOF agrees that it shall supply to CREALTA additional quantities of Activated PEG as CREALTA may
require for up to an additional period of twenty-four (24) months subsequent to the effective date of termination, provided, however, CREALTA shall provide to NOF with Forecasts, Firm Forecasts and purchase orders setting forth the quantities
of Activated PEG to be supplied by NOF pursuant to this provision, all in accordance with the terms of this Agreement. 

  

	8.7	 Intentionally Blank. 

 

	8.8	 Survival. The following Sections shall survive termination of this Agreement: 3.1, 3.2, 3.3, 3.4,
Article 4, Article 5, Article 6, 7.1, 7.3, 8.6 and any other Section which by its wording implies that it is intended to survive the termination or expiration of this Agreement. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 13 

 ARTICLE 9 

MISCELLANEOUS PROVISIONS 
  

	9.1	 Assignment. Neither this Agreement, any rights nor any interest hereunder shall be assignable by either
Party without prior written consent of the other Party, such consent not to be unreasonably withheld, except that this Agreement may be assigned by either Party without consent to a Third Party that acquires more than fifty percent (50%) of such
Party’s assets. This Agreement shall be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the name of such Party’s successors and permitted assigns to the
extent necessary to carry out the intent of this Agreement. Any assignment that does not comply with this Section shall be void. 

  

	9.2	 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to
do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

  

	9.3	 Notices. All notices and other communications hereunder shall be in writing and shall be deemed
given if delivered personally by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by courier services, to the Parties at the following addresses (or at such other
address for a Party as shall be specified by like notice, provided, however, that notices of a change of address shall be effective only upon receipt thereof): 

If to CREALTA, addressed to: 

CREALTA Pharmaceuticals LLC 
 150
S. Saunders Rd., Suite 130 
 Lake Forest, IL 60045 USA 

Attn: Sr. Director Global Supply Chain 

Fax: +01-847-234-0019

 If to NOF, addressed to: 

NOF CORPORATION 
 Yebisu Garden
Place Tower 
 20-3, Ebisu 4-chome, 

Sibuya-ku, Tokyo, 150-6019, Japan 

Attention: DDS Development Department 

Fax: +81-3-5424-6769 

 

	9.4	 Amendment. No amendment, modification or supplement of any provision of this Agreement shall be valid or
effective unless made in writing and signed by a duly authorized officer of each Party. 

  
 14 

	9.5	 Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of any Party or
its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. 

  

	9.6	 Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be
of no force or effect in construing or interpreting any of the provisions of this Agreement. 

  

	9.7	 Governing Law. This Agreement shall be governed by and interpreted in accordance with the substantive
laws of the State of Delaware, USA. 

  

	9.8	 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of this Agreement. 

  

	9.9	 No Publicity. No oral or written release of any statement, information, advertisement, press release or
publicity matter having any reference to either Party, express or implied, shall be used by the other Party or on the other Party’s behalf, unless and until such matter shall have first been submitted to and received the approval in writing of
the Party whose name is being used. 

  

	9.10	 Dispute Resolution. All disputes, controversies or differences which may arise between the Parties
hereto, out of or in relation to or in connection with this Agreement, which cannot be satisfactorily settled by the Parties, shall be finally settled by arbitration in the State of New York, the United State of America, pursuant to the Commercial
Arbitration Rules of the American Arbitration Association. The arbitration proceedings shall be conducted in the English language. The award shall be final and binding upon both Parties. Judgment upon the award may be entered in any court having
jurisdiction thereof. 

  

	9.11	 Independent Contractors. This relationship between Parties created by this Agreement is one of
independent contractors and neither Party shall have the power or authority to bind or obligate the other except as expressly set forth in this Agreement. 

  

	9.12	 Force Majeure. Neither Party shall be liable to the other for loss or damages or shall have any right to
terminate this Agreement for any default or delay attributable to any Force Majeure, if the Party affected shall give prompt notice of any such Force Majeure to the other Parties. The Party giving such notice shall thereupon be excused from such of
its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled, provided, however, that such affected Party shall have used reasonable efforts to avoid such occurrence and to commence and continue to take
reasonable and diligent actions to cure such Force Majeure. 

  

	9.13	 Entire Agreement. This Agreement constitutes and contains the complete, final and exclusive
understanding and agreement of the Parties and cancels and supersedes any and all prior 

  
 15 

	 	
negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof. 

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first above written. 

 

									
	 Signed for and on behalf of

CREALTA Pharmaceuticals LLC
	 		 	 Signed for and on behalf of

NOF CORPORATION

					
	Signature	 	 /s/ Richard Crowley
	 		 	Signature	 	 /s/ [***]

	Name:	 	Richard Crowley	 		 	Name:	 	[***]
	Position:	 	Sr. VP operations and QA	 		 	Position:	 	[***]
	Date:	 	August 11, 2015	 		 	Date:	 	August 5, 2015

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 16 

 Exhibit A: Specification 

 

									
	 Parameter
	  	Specification	 	  	Test	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 17 

 Exhibit B: CREALTA’s Minimum Purchase Obligations on a per Year basis 

There will be no minimum annual purchase quantities. The only obligation for purchase of activated PEG is specified in Section 3.2. 

  
 18 

 Exhibit C: Supply Price (price per purchase order quantity) 

 

			
	 Amount Purchased during

Year (Forecast)
	  	 Price per [***] ordered

during Year

	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 19 

 Exhibit D: Quality Agreement 

Supplier Quality Assurance Agreement 

for NOF Corporation 
 Version 1.0
(DRAFT) 
 CREALTA 

PHARMACEUTICALS LLC 
 CREALTA
Pharmaceuticals LLC 
 150 S. Saunders Rd., Suite 130 

Lake Forest, IL 60045 

  
 20 

	1.0	 Purpose and Scope 

The following document defines the Quality Assurance (QA) responsibilities between CREALTA Pharmaceuticals LLC (CREALTA) and NOF Corporation
(NOF). This agreement applies to all product(s) pursuant to the Supply Agreement entered into between CREALTA and NOF. 
  

	2.0	 General 

  

	 	2.1.	 Approval of this Quality Agreement implies adherence by both parties to applicable regulatory requirements for
the manufacture of pharmaceutical or biological products, or products used in finished drug products, as defined in 21 CFR Part 210 and the International Conference on Harmonization guidance Q7A, Good Manufacturing Practices for Active
Pharmaceutical Ingredients. 

  

	 	2.2.	 NOF will make available to CREALTA any relevant information, documents, and/or data pertaining to the
manufacturing and testing of product(s). 

  

	 	2.3.	 Effective date of this Quality Agreement is the date of the last approval signature. 

 

	 	2.4.	 CREALTA responsibilities or activities as stated in this Agreement shall in no way relieve NOF of any
obligations under this Agreement. 

  

	 	2.5.	 All Agreement amendments must be documented as an addendum. All amendments must be approved, at a minimum, by
CREALTA QA and NOF QA. Legal and Regulatory review and/or approval shall be considered. 

  

	3.0	 Definitions 

  

	 	3.1.	 Business Day shall mean Monday through Friday excluding government holidays. 

 

	 	3.2.	 Deviation shall mean an event or result that is different from the expected event or result as defined in
procedures. 

  

	 	3.3.	 Out of Specification (OOS) shall mean any intermediate or finished product test result that is different from
the result defined in the specification. 

  

	4.0	 cGMP Quality Systems and cGMP Activities 

 

	 	4.1.	 Manufacturing and Sampling 

 

	 	4.1.1.	 NOF shall manufacture and sample according to NOF approved procedures and batch records. 

 

	 	4.1.2.	 NOF shall sample and retain sufficient amounts of all product lots in accordance with current good
manufacturing practices (cGMP). 

  
 21 

	 	4.2.	 Testing and Conformance 

 

	 	4.2.1.	 NOF will test all product(s) intended for use by CREALTA or CREALTA’s third-party contractors per
validated and NOF approved methods. 

  

	 	4.2.2.	 NOF will ensure test results are compared to, and meet, approved product specification. 

 

	 	4.2.3.	 All OOS and atypical results will be managed according to NOF approved deviation procedures.

  

	 	4.3.	 Stability 

  

	 	4.3.1.	 NOF shall perform the appropriate stability testing to ensure a minimum expiry period of [***] from the date of
manufacture. 

  

	 	4.3.2.	 Stability testing and program shall be defined by NOF approved procedures. 

 

	 	4.4.	 Disposition 

  

	 	4.4.1.	 All products shall have a disposition status of Quarantine, Released / Approved, or Rejected.

  

	 	4.4.2.	 Only products with a Released or Approved status shall be transferred to CREALTA or CREALTA third-party
contractors (refer to Section 3.4 of the Supply Agreement). 

  

	 	4.4.3.	 CREALTA, or CREALTA’s third-party contractors, shall have the right to reject within [***] calendar days
any lot/batch of product which fails to conform to the applicable specifications or otherwise fails to conform to warranties given by NOF set forth in ARTICLE 5 of the Supply Agreement, provided that the failure to conform is not due to any action
or inaction on the part of CREALTA or CREALTA’s third-party contractors. Any such rejection shall be made in writing to NOF from CREALTA specifying the manner in which all or part of the batch fails to meet the requirements. Refer to
Section 4 of the Supply Agreement for returning to NOF those lots/batches which fail to conform. 

  

	 	4.4.4.	 Disposition shall be controlled by NOF approved procedures. 

 

	 	4.5.	 Labeling 

  

	 	4.5.1.	 Products shall be appropriately labeled to ensure product identity, lot number, product code, expiration and/or
retest date(s), handling and storage requirements. 

  

	 	4.5.2.	 Labeling shall be controlled by NOF approved procedures. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 22 

	 	4.6.	 Handling and Shipping 

 

	 	4.6.1.	 All products shall be handled and shipped in such a manner that shall ensure product quality.

  

	 	4.6.2.	 Prior to shipping, all product containers will be inspected by NOF for integrity, cleanliness, and appropriate
labeling. 

  

	 	4.6.3.	 Product shipped shall have a minimum remaining expiry of [***]. 

 

	 	4.6.4.	 A Certificate of Analysis (C of A) will be provided for each product lot shipped (refer to Section 3.4 of
the Supply Agreement). 

  

	 	4.6.5.	 C of A shall contain at least the product name, lot/batch number, tests, specifications, results, manufacturing
date and location, expiration date/retest date, and appropriate approvals. 

  

	 	4.6.6.	 Handling and shipping shall be controlled by NOF approved procedures. 

 

	 	4.7.	 Change Control 

  

	 	4.7.1.	 Planned deviations made to the manufacturing process, testing, and other processes used to ensure product
quality must be managed through a formal change management process or a formal deviation management process. 

  

	 	4.7.2.	 NOF will utilize a documented system for the control of changes to raw materials, packaging materials,
suppliers, manufacturing facilities, equipment, manufacturing processes, batch size, specifications, sampling, testing, disposition requirements, and certificates of analysis. 

 

	 	4.7.3.	 Critical change shall be reviewed and approved by CREALTA QA, CREALTA Manufacturing, and CREALTA Regulatory in
writing prior to implementation. 

  

	 	4.7.4.	 CREALTA Regulatory shall have the responsibility for determining the regulatory impact of any proposed change.
CREALTA Regulatory will determine the classification and requirements for notification to, or approval by, the FDA. 

  

	 	4.7.5.	 CREALTA is responsible for communicating any changes to the FDA relative to the finished drug product and / or
any application to which CREALTA is the sponsor. 

  

	 	4.7.6.	 NOF will ensure that all changes are evaluated and qualified in accordance with FDA and International
Conference on Harmonization (ICH) guidance documents. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 23 

	 	4.8.	 Corrective Action / Preventive Action (CAPA) 

 

	 	4.8.1.	 NOF will have a formal CAPA program to ensure unplanned deviations are identified and corrected following
occurrence, and potential deviations are identified and prevented prior to occurrence. 

  

	 	4.8.2.	 Critical unplanned deviation shall be communicated to CREALTA prior to the shipment to CREALTA.

  

	 	4.8.3.	 Any unplanned deviation from the manufacturing process, testing, and other processes used to ensure product
quality must be managed through a formal investigation system defined by procedures. 

  

	 	4.8.4.	 All unplanned deviations will be thoroughly and appropriately investigated in order to identify root cause(s)
and corrective actions in a timely manner. 

  

	 	4.8.5.	 NOF will utilize a documented system for control of investigations and corrective and preventive action(s).

  

	 	4.8.6.	 Unplanned deviations shall be identified prior to product disposition. 

 

	 	4.9.	 Audits 

  

	 	4.9.1.	 Internal 

  

	 	a.	 NOF shall have a formal internal audit process controlled by NOF approved procedures. 

 

	 	4.9.2.	 Supplier 

  

	 	a.	 CREALTA shall have the authority to audit NOF at most [***] per calendar year. 

 

	 	b.	 Audits shall not exceed [***] business days, unless otherwise agreed upon by NOF and CREALTA.

  

	 	c.	 CREALTA has the authority to request additional audits should quality issues dictate. NOF shall make every
reasonable attempt to accommodate such requests. 

  

	 	d.	 CREALTA shall provide NOF with a written report within [***] business days following audit completion.

  

	 	e.	 NOF shall provide CREALTA with a written response to the audit report detailing corrective / preventive
action(s) within [***] business days following receipt of CREALTA’s audit report. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 24 

	 	f.	 CREALTA shall review NOF’s response and provide written approval of action(s) or request additional
information within [***] business days following the receipt of NOF’s response. 

  

	 	g.	 Reasonable attempts shall be made by both parties to reach an agreeable conclusion in a timely manner.

  

	 	4.9.3.	 Regulatory 

  

	 	a.	 NOF will communicate within [***] business days any Regulatory audit observations that impact the quality of
product(s) supplied to CREALTA or CREALTA third-party contractors. 

  

	 	4.10.	 Equipment and Facilities 

 

	 	4.10.1.	 Validation 

  

	 	a.	 All equipment and facilities used to manufacture and test products intended for transfer to CREALTA or CREALTA
third-party contractors shall be validated to ensure adequacy for intended use. 

  

	 	b.	 NOF shall have a formal validation process that includes validation and
re-validation requirements. 

  

	 	c.	 Validation shall be controlled by NOF approved procedures. 

 

	 	4.10.2.	 Maintenance 

  

	 	a.	 Equipment and facilities shall be maintained to ensure product quality. 

 

	 	b.	 NOF shall have a formal maintenance program that includes procedures defining periodic and preventive
maintenance, documentation, and work orders. 

  

	 	c.	 Maintenance shall be controlled by NOF approved procedures. 

 

	 	4.10.3.	 Environment 

  

	 	a.	 The manufacturing and testing conducted by NOF shall be in suitably controlled environments, and will be
regularly monitored for parameters critical to the process. 

  

	 	b.	 Facilities shall provide adequate space to prevent product mix-up and
contamination. 

  

	 	c.	 Activities shall be controlled by NOF approved procedures. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 25 

	 	4.11.	 Training 

  

	 	4.11.1.	 Personnel shall be trained on applicable procedures and systems. 

 

	 	4.11.2.	 NOF shall have a formal training program to ensure personnel are adequately trained and qualified to perform
assigned activities. 

  

	 	4.11.3.	 Training shall be controlled by procedures. 

 

	 	4.12.	 Organization and Personnel 

 

	 	4.12.1.	 NOF shall have adequate staffing to ensure product quality, adherence to requirements, and management
oversight. 

  

	 	4.12.2.	 Personnel shall have job descriptions. 

 

	 	4.12.3.	 The Quality Unit shall have the appropriate authority to ensure product quality and compliance.

  

	 	4.13.	 Documentation 

  

	 	4.13.1.	 All GMP activities shall be governed by NOF QA reviewed and approved standard operating procedures.

  

	 	4.13.2.	 All GMP activities shall be recorded. 

 

	 	4.13.3.	 NOF shall have formal systems to ensure GMP activities are recorded and that all GMP documents are maintained,
controlled, and retained. 

  

	 	4.13.4.	 CREALTA, or CREALTA’s third-party contractors, shall have access to all documentation for the product(s)
provided to CREALTA or CREALTA’s third-party contractors on reasonable notice and during normal business hours. Such requests shall be made during audits. 

 

	 	4.13.5.	 NOF will assist CREALTA or CREALTA’s third-party contractors when documents other than those typically
maintained by NOF are required in case of requirement from regulatory authority. 

  

	 	4.13.6.	 Documentation shall be controlled by procedures. 

 

	 	4.14.	 Resolution of Quality Issues 

 

	 	4.14.1.	 NOF shall make reasonable effort to correct, in accordance with this agreement, all quality issues.

  

	 	4.14.2.	 NOF and CREALTA shall communicate openly regarding quality issues and reasonable attempts at issue resolution
shall be made. 

  
 26 

	 	4.14.3.	 Unresolved issues shall be elevated to the appropriate NOF and CREALTA leadership. 

 

	 	4.15.	 Product Review 

  

	 	4.15.1.	 Products shall be reviewed periodically to ensure a consistent, quality product is produced.

  

	 	4.15.2.	 Documentation and system reviews shall be conducted periodically to ensure changes and corrective / preventive
actions did not adversely impact product quality. 

  
 27 

 Revision History 

 

									
	 Effective Date
	  	Version	  	Changes	  	Prepared By	 
	 Date of last approval signature
	  	1.0	  	New Quality
 Agreement
	  			

  
 28 

 Approvals 
  

													
	  	  	Print Name	 	  	Signature	 	  	Date	 
	 Prepared
By
	  	 	 	 	  	 	 	 	  	 	 	 
	 	 	 	 
	 CREALTA

Quality

Assurance
	  			 	  			 	  			 
	 	 	 	 
	 CREALTA

Regulatory
	  			 	  			 	  			 
	 	 	 	 
	 NOF

Quality

Assurance:
	  			 	  			 	  			 
	 	 	 	 
	 NOF

Manufacturing
	  	 	 	 	  	 	 	 	  	 	 	 

  
 29 

 Exhibit E: CREALTA Products 

As used in this Agreement, “CREALTA Products” shall mean [***]. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 30EX-10.23

 Exhibit 10.23 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE HORIZON THERAPEUTICS PLC HAS
DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO HORIZON THERAPEUTICS PLC IF PUBLICLY DISCLOSED. 

EXECUTION COPY 
 ASSET
PURCHASE AGREEMENT 
 between 

UCYCLYD PHARMA, INC., 

and 
 HYPERION
THERAPEUTICS, INC. 
 dated as of 

March 22, 2012 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE I
	 	 Definitions
	  	 	1	 
			
	 ARTICLE II
	 	 Purchase and Sale
	  	 	10	 
			
	 Section 2.01
	 	 Purchase and Sale of Assets
	  	 	10	 
			
	 Section 2.02
	 	 Excluded Assets
	  	 	11	 
			
	 Section 2.03
	 	 Assumed Liabilities
	  	 	11	 
			
	 Section 2.04
	 	 Excluded Liabilities
	  	 	12	 
			
	 Section 2.05
	 	 Purchase Price
	  	 	13	 
			
	 Section 2.06
	 	 Financial Audit and Record-Keeping Requirements
	  	 	14	 
			
	 Section 2.07
	 	 Withholding Tax
	  	 	14	 
			
	 Section 2.08
	 	 Third Party Consents
	  	 	14	 
			
	 ARTICLE III
	 	 Closing
	  	 	15	 
			
	 Section 3.01
	 	 Closing
	  	 	15	 
			
	 Section 3.02
	 	 Closing Deliverables
	  	 	15	 
			
	 ARTICLE IV
	 	 Other Rights and Licenses
	  	 	16	 
			
	 Section 4.01
	 	 Licenses to Buyer
	  	 	16	 
			
	 Section 4.02
	 	 Licenses to Seller
	  	 	18	 
			
	 Section 4.03
	 	 Retained Know-How
	  	 	20	 
			
	 Section 4.04
	 	 Covenant Not to Assert
	  	 	20	 
			
	 Section 4.05
	 	 No Contest
	  	 	20	 
			
	 Section 4.06
	 	 Mutual Release
	  	 	21	 
			
	 ARTICLE V
	 	 Representations and Warranties of Seller
	  	 	21	 
			
	 Section 5.01
	 	 Organization of Medicis and Seller
	  	 	21	 
			
	 Section 5.02
	 	 Authority of Medicis and Seller
	  	 	21	 
			
	 Section 5.03
	 	 No Conflicts; Consents
	  	 	22	 
			
	 Section 5.04
	 	 Title to Assets
	  	 	23	 
			
	 Section 5.05
	 	 No Third Party Rights
	  	 	23	 
			
	 Section 5.06
	 	 HPN-100 Patents
	  	 	23	 
			
	 Section 5.07
	 	 Brokers
	  	 	23	 
			
	 Section 5.08
	 	 No Licenses or Liens
	  	 	23	 
			
	 Section 5.09
	 	 Assigned Contracts
	  	 	23	 

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

							
			
	 	 	 	  	Page	 
	 Section 5.10
	 	 No Breach
	  	 	24	 
			
	 Section 5.11
	 	 Brusilow/Summar Agreements
	  	 	24	 
			
	 Section 5.12
	 	 No Invalidity
	  	 	24	 
			
	 Section 5.13
	 	 No Infringement
	  	 	24	 
			
	 Section 5.14
	 	 Third Party Agreements
	  	 	24	 
			
	 Section 5.15
	 	 Right to Grant Licenses
	  	 	24	 
			
	 Section 5.16
	 	 All Necessary Rights
	  	 	24	 
			
	 ARTICLE VI
	 	 Representations and Warranties of Buyer
	  	 	24	 
			
	 Section 6.01
	 	 Organization of Buyer
	  	 	25	 
			
	 Section 6.02
	 	 Authority of Buyer
	  	 	25	 
			
	 Section 6.03
	 	 No Conflicts; Consents
	  	 	25	 
			
	 Section 6.04
	 	 Brokers
	  	 	25	 
			
	 Section 6.05
	 	 Sufficiency of Funds
	  	 	26	 
			
	 Section 6.06
	 	 Legal Proceedings
	  	 	26	 
			
	 ARTICLE VII
	 	 Covenants
	  	 	26	 
			
	 Section 7.01
	 	 Confidentiality; Public Disclosure
	  	 	26	 
			
	 Section 7.02
	 	 Non-competition
	  	 	27	 
			
	 Section 7.03
	 	 Transfer of Product Registrations
	  	 	29	 
			
	 Section 7.04
	 	 Governmental Approvals and Consents
	  	 	30	 
			
	 Section 7.05
	 	 Patent Prosecution and Maintenance
	  	 	31	 
			
	 Section 7.06
	 	 Bulk Sales Laws
	  	 	32	 
			
	 Section 7.07
	 	 Transfer Taxes
	  	 	32	 
			
	 Section 7.08
	 	 Technology Transfer and Product Records
	  	 	32	 
			
	 Section 7.09
	 	 Perfection of IP Rights
	  	 	32	 
			
	 Section 7.10
	 	 Further Assurances
	  	 	33	 
			
	 Section 7.11
	 	 Adverse Events and Safety Reporting
	  	 	33	 
			
	 ARTICLE VIII
	 	 Indemnification
	  	 	33	 
			
	 Section 8.01
	 	 Survival
	  	 	33	 
			
	 Section 8.02
	 	 Indemnification By Seller
	  	 	33	 

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

							
			
	 	 	 	  	Page	 
	 Section 8.03
	 	 Indemnification By Medicis
	  	 	34	 
			
	 Section 8.04
	 	 Indemnification By Buyer
	  	 	34	 
			
	 Section 8.05
	 	 Certain Limitations
	  	 	35	 
			
	 Section 8.06
	 	 Indemnification Procedures
	  	 	35	 
			
	 Section 8.07
	 	 Payments
	  	 	37	 
			
	 Section 8.08
	 	 Tax Treatment of Indemnification Payments
	  	 	38	 
			
	 Section 8.09
	 	 Effect of Investigation
	  	 	38	 
			
	 Section 8.10
	 	 Exclusive Remedies
	  	 	38	 
			
	 ARTICLE IX
	 	 Termination
	  	 	38	 
			
	 Section 9.01
	 	 Termination of Licenses
	  	 	38	 
			
	 ARTICLE X
	 	 Miscellaneous
	  	 	39	 
			
	 Section 10.01
	 	 Expenses
	  	 	39	 
			
	 Section 10.02
	 	 Notices
	  	 	39	 
			
	 Section 10.03
	 	 Interpretation
	  	 	40	 
			
	 Section 10.04
	 	 Headings
	  	 	41	 
			
	 Section 10.05
	 	 Severability
	  	 	41	 
			
	 Section 10.06
	 	 Entire Agreement
	  	 	41	 
			
	 Section 10.07
	 	 Successors and Assigns
	  	 	41	 
			
	 Section 10.08
	 	 No Third-party Beneficiaries
	  	 	41	 
			
	 Section 10.09
	 	 Amendment and Modification; Waiver
	  	 	41	 
			
	 Section 10.10
	 	 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial
	  	 	42	 
			
	 Section 10.11
	 	 Specific Performance
	  	 	44	 
			
	 Section 10.12
	 	 Counterparts; Electronic Documents
	  	 	44	 

  
 -iii- 

 ASSET PURCHASE AGREEMENT 

This Asset Purchase Agreement (this “Agreement”), dated as of March 22, 2012 (the “Signing Date”) is
entered into among Ucyclyd Pharma, Inc., a Maryland corporation (“Seller”), Hyperion Therapeutics, Inc., a Delaware corporation (“Buyer”) and solely for the purposes set forth above its signature to this Agreement,
Medicis Pharmaceutical Corporation, a Delaware corporation (“Medicis”). 
 RECITALS 

WHEREAS, Seller is the owner of certain assets related to the development product currently referred to as
HPN-100 (and formerly referred to as GT4P under the Prior Collaboration Agreement), which has been developed by Buyer for use in the treatment of urea cycle disorders and hepatic encephalopathies under the
terms of the Prior Collaboration Agreement; and 
 WHEREAS, Seller wishes to sell and assign to Buyer, and Buyer wishes to purchase and
assume from Seller, all of Seller’s rights, title, and interest in the Product (including certain specified liabilities), subject to the terms and conditions set forth herein; 

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 
 ARTICLE I 

DEFINITIONS 
 The following
terms have the meanings specified or referred to in this Article I: 
 “Action” means any claim, action, cause
of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.

 “Active Moiety Product” means any product that comprises, incorporates or contains, in whole or in part, sodium
phenylbutyrate or glycerol phenylbutyrate as an active pharmaceutical ingredient or any other active pharmaceutical ingredient that is, or converts to, phenylacetate. 

“Affiliate” of a Person means any other Person that directly or indirectly, controls, is controlled by, or is under
common control with, such Person. For purposes of this definition, the term “control” (including, with correlative meaning, the terms “controlled by” and “under common control with”) means the actual power, either
directly or indirectly through one or more 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 1 of 45 

 
intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, or
by contract or otherwise. For purposes of this Agreement, the term “control” shall not apply to Persons that are venture capital or similar investment funds, and that acquired an ownership stake in a Party solely as a result of one or a
series of bona fide private equity financings. 
 “Agreement” has the meaning set forth in the preamble. 

“Amended and Restated Collaboration Agreement” means the Amended and Restated Collaboration by and between Seller and
Buyer, effective as of March 22, 2012. 
 “Ammonul” means (a) the pharmaceutical product that Ucyclyd (directly
or through its Affiliates or distributors) markets or sells in the United States pursuant to NDA 20-645 and any supplements thereto and (b) any other products that Ucyclyd (directly or through its
Affiliates or distributors) markets or sells anywhere in the world that (i) contain the same combination of active pharmaceutical ingredients as the foregoing, (ii) are marketed or sold under the name “Ammonul” and
(iii) have been approved by applicable Governmental Authorities for the treatment of UCD. 
 “Arbitration Panel” has
the meaning set forth in Section 10.10(b)(ii). 
 “Assets” has the meaning set forth in
Section 2.01. 
 “Assigned Contracts” has the meaning set forth in
Section 2.01(e). 
 “Assignment and Assumption Agreement” has the meaning set forth in
Section 3.02(a)(ii). 
 “Assumed Liabilities” has the meaning set forth in
Section 2.03. 
 “Assumed Payments” has the meaning set forth in
Section 2.05(d). 
 “Bill of Sale” has the meaning set forth in
Section 3.02(a)(i). 
 “Brusilow Amendment” means that certain Settlement Agreement and
First Amendment dated August 21, 2007 among Dr. Saul Brusilow, Brusilow Enterprises, LLC, and Seller (a subsidiary of Medicis). 

“Brusilow License Agreement” means, collectively, the Brusilow Original Agreement and the Brusilow Amendment. 

“Brusilow Original Agreement” means that certain License Agreement, dated April 16, 1999, among Dr. Saul
Brusilow, Brusilow Enterprises, LLC, and Seller (as successor in interest to Medicis). 
 “Brusilow Parties” means
Dr. Saul Brusilow and Brusilow Enterprises, LLC. 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 2 of 45 

 “Buphenyl” means (a) Buphenyl Powder, (b) Buphenyl Tablets,
(c) the products that Ucyclyd (directly or through its Affiliates or distributors) markets or sells in the European Union under the name “Ammonaps” (EMA Product Number EMEA/H/C/000219), and (d) any other products that Ucyclyd
(directly or through its Affiliates or distributors) markets or sells throughout the world that (i) contain sodium phenylbutyrate as the sole active pharmaceutical ingredient, (ii) are marketed or sold under the name “Buphenyl”
or “Ammonaps,” and (iii) have been approved by applicable Governmental Authorities for the treatment of UCD. 

“Buphenyl Powder” means the pharmaceutical product that Ucyclyd (directly or through its Affiliates or distributors)
markets or sells in the United States pursuant to NDA 20-573 and any supplements thereto. 

“Buphenyl Tablets” means the pharmaceutical products that Ucyclyd (directly or through its Affiliates or distributors)
markets or sells in the United States pursuant to NDA 20-572 and any supplements thereto. 

“Business” means the research, development, registration, commercialization, or any other use or exploitation of the
Product. 
 “Business Day” means any day except Saturday, Sunday or any other day on which commercial banks located in
New York are authorized or required by Law to be closed for business. 
 “Buyer” has the meaning set forth in the
preamble. 
 “Buyer Indemnitees” has the meaning set forth in Section 8.02. 

“Buyer Party” has the meaning set forth in Section 4.04. 

“Buyer Product Data” has the meaning set forth in Section 4.02(a). 

“Buyer Section 8.05(a) Basket Exclusions” has the meaning set forth in
Section 8.05(a). 
 “Buyer Section 8.05(c) Basket Exclusions” has the
meaning set forth in Section 8.05(c). 
 “Change in Control” means the consummation of:
(a) any merger, consolidation, business combination or sale of shares of stock other than in a direct issuance of shares of stock by a Party for fair value, that, if completed, will result in the stockholders of such Party prior to such
transaction not having voting control of the surviving entity immediately after the transaction such that they, acting in concert with one another, could not elect a majority of the board of directors of the surviving entity; or (b) the sale,
transfer, exchange or other disposition of all or substantially all of a Party’s assets or business relating to this Agreement (whether alone or in connection with a sale, transfer, exchange or other disposition of other assets or businesses of
such Party). Notwithstanding the foregoing, Change in Control shall not include a financing transaction, either in the form of a private equity financing or public offering. 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 3 of 45 

 “Closing” has the meaning set forth in
Section 3.01. 
 “Code” means the Internal Revenue Code of 1986, as amended. 

“Contingent Payments” has the meaning set forth in Section 2.05(b). 

“Direct Claim” has the meaning set forth in Section 8.06(c). 

“Disclosure Schedules” means the Disclosure Schedules delivered by Seller and Buyer concurrently with the execution and
delivery of this Agreement. 
 “Distributor Territories” has the meaning set forth in
Section 4.01(b)(i). 
 “Dollars or $” means the lawful currency of the United States. 

“Excluded Assets” has the meaning set forth in Section 2.02. 

“Excluded Contracts” has the meaning set forth in Section 2.02(a). 

“Excluded Liabilities” has the meaning set forth in Section 2.04. 

“Existing Product” means the Product as described in (a) the NDA that Buyer submitted to FDA on December 23, 2011
for the treatment of UCD, or (b) the IND for the treatment of HE. It is acknowledged that an Existing Product may be used to treat UCD and HE in additional patient populations beyond those covered by the foregoing NDA and IND and that this
definition of Existing Product is not intended to exclude Product merely because it is used in such additional patient populations. For clarity, the Existing Product is intended for oral or other gastrointestinal administration, and any Product
intended for other routes of administration is not an Existing Product. 
 “Existing Product Indications” means UCD and HE.

 “FDA” means the United States Food and Drug Administration, or any successor agency thereto. 

“FDA Transfer of Ownership Letter” means the letter submitted by each of the Parties and the application form submitted
by Buyer to the FDA notifying the agency of the change in ownership of the NDA in accordance with Title 21 of the Code of Federal Regulations, Section 314.72. 

“Governmental Authority” means any any court, tribunal, arbitrator, agency, legislative body, commission, official or
other instrumentality of: (a) any government of any country; or (b) a federal, state, province, county, city or other political subdivision thereof. 

“Governmental Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by
or with any Governmental Authority. 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 4 of 45 

 “HE” means hepatic encephalopathy or hepatic encephalopathies. 

“HPN-100 Know-How” means: (a) Know-How (other than Ucyclyd Manufacturing Know-How) used for, or prepared in connection with, the development or commercialization of the Product that is
(i) owned by Seller, or (ii) in-licensed by Seller to the extent licensable or assignable to Buyer; and (b) any and all intellectual property rights in or to any of the foregoing (other than
Patents). 
 “HPN-100 Patents” means the Patents set forth on Schedule
2.01(c), along with any (a) any substitutions, divisions, continuations, or continuations-in-part thereof, (b) any Patents claiming priority to or issuing
from any of the foregoing; and (c) any reissues, renewals, registrations, confirmations, re-examinations and extensions of such Patents, in each case anywhere in the world. 

“HPN-100 Technology” means HPN-100
Patents and HPN-100 Know-How. 
 “Hyperion
Manufacturing Technology” means (a) any Know-How for the manufacture or supply of Product that (i) was developed by Buyer and that is owned by Seller under the Prior Collaboration
Agreement, or (ii) was otherwise developed or acquired by Seller on or after August 23, 2007, (b) any and all intellectual property rights in or to any of the foregoing (other than Patents), and (c) any Patents arising from any
of the foregoing. 
 “IND” means an investigational new drug application submitted by a sponsor to the FDA pursuant to
21 C.F.R. Part 312, or to the extent applicable outside the United States, any other similar application submitted to the appropriate Governmental Authority in a country or group of countries other than the United States, and any supplements or
amendments to any of the foregoing 
 “Indemnified Party” has the meaning set forth in
Section 8.06. 
 “Indemnifying Party” has the meaning set forth in
Section 8.06. 
 “Initial Purchase Price” has the meaning set forth in
Section 2.05(a). 
 “Know-How” means any and all
technical, scientific, regulatory, clinical, medical, marketing, sales, financial and business information and data, know-how, formulations, trade secrets, techniques, processes, ideas, concepts, designs,
original works of authorship, enhancements, derivative works, adaptations, discoveries and inventions. 
 “Knowledge of
Buyer” or “Buyer’s Knowledge” or any other similar knowledge qualification with respect to the Buyer, means the actual knowledge of the Chief Executive Officer of Buyer, the [***] of Buyer, or the [***] of
Buyer. 
 “Knowledge of Seller” or “Seller’s Knowledge” or any other similar knowledge
qualification with respect to the Seller, means the actual knowledge of (a) the President and Chief Executive Officer of Seller or the Executive Vice President, Chief Financial Officer and 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 5 of 45 

 
Treasurer of Seller and (b) with respect to Section 5.09, Section 5.11, Section 5.12 and Section 5.13 only, the
President and Chief Executive Officer of Seller, the Executive Vice President, Chief Financial Officer and Treasurer of Seller, or [***] for Medicis and its Affiliates. 

“Law” means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment,
decree, other requirement or rule of law of any Governmental Authority. 
 “Liabilities” means liabilities,
obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise. 

“Lien” means any mortgage, lien (including mechanics, warehousemen, laborers and landlords liens), pledge, hypothecation,
charge, community property interest, equitable interest, security interest, pre-emptive right, right of first refusal or similar restriction or right, option, judgment or title defect. 

“Losses” means losses, damages, liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs
or expenses of whatever kind, including reasonable attorneys’ fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers; provided, however, that “Losses” shall not
include punitive, indirect, special, incidental or consequential damages, except (a) in the case of fraud, (b) to the extent actually awarded to a Governmental Authority or other Third Party or (c) for consequential damages arising
out of a breach by Seller of [***], or by Medicis of [***], or by Buyer of [***]. 
 “Major
Non-U.S. Territory” has the meaning set forth in Schedule 2.05(b). 

“Marketed Products Pre-Closing Period” means the
“Pre-Closing Period,” as defined in the Amended and Restated Collaboration Agreement. 

“Marketed Products Rights” has the meaning set forth in Section 3.1 of the Amended and Restated Collaboration Agreement.

 “Marketed Products Technology” has the meaning given to such term in the Amended and Restated Collaboration
Agreement. 
 “Material Adverse Effect” means any event, occurrence, fact, condition or change that is, individually
or in the aggregate, materially adverse to the results of operations, prospects, condition (financial or otherwise) or assets of the Business; provided, however, that “Material Adverse Effect” shall not include any event,
occurrence, fact, condition, or change, directly or indirectly, arising out of or attributable to: (a) any changes, conditions or effects in the United States economy or securities or financial markets in general; (b) changes, conditions
or effects that generally affect the industries in which the Business operates; (c) any change, effect or circumstance resulting from an action required or permitted by this Agreement, except pursuant to Section 5.03
and Section 7.07; (d) conditions caused by acts of terrorism or war (whether or not declared); or (e) conditions caused by Buyer or its Affiliates; provided further, however, that

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 6 of 45 

 
with respect to the NDA filed for HPN-100, FDA’s non-acceptance of the application and a Complete Response
Letter are not considered events having a Material Adverse Effect. 
 “Medicis” has the meaning set forth in the
preamble. 
 “NDA” means any new drug application that is submitted pursuant to the requirements of the FDA, 21 C.F.R.
Part 314, or to the extent applicable outside the United States, any other similar application submitted to the appropriate Governmental Authority in a country or group of countries other than the United States, and any supplements or amendments to
any of the foregoing. 
 “New Indications” has the meaning set forth in Section 4.02(c). 

“Other Indication” means treatment for any disease other than UCD or HE. 

“Parties” means, collectively, the Seller, Buyer and, solely for the purposes set forth above its signature to this
Agreement, Medicis. 
 “Party” means Seller, Buyer or Medicis as the context so requires. 

“Patents” means all: (a) U.S. issued patents (including re-examinations,
reissues, renewals, and all extensions and term restorations), inventors’ certificates and foreign counterparts thereof; (b) pending applications for U.S. patents, including provisional applications, continuations, continuations- in-part, continued prosecution, divisional and substitute applications; and (c) non-U.S. counterparts or equivalents of the foregoing in subsections (a) and
(b). 
 “Permit” means any permit, license, approval, consent or authorization issued by a Governmental Authority.

 “Permitted Encumbrances” means those items set forth in Section 5.08 of the Disclosure
Schedules. 
 “Person” means an individual, corporation, partnership, joint venture, limited liability company,
Governmental Authority, unincorporated organization, trust, association or other entity. 

“Pre-Closing Tax Period” means any taxable period ending on or before the
Signing Date and, with respect to any taxable period beginning before and ending after the Signing Date, the portion of such taxable period ending on and including the Signing Date. 

“Price Approval” means, with respect to any country in which the price at which the applicable products are to be sold
must be approved by a Governmental Authority for reimbursement or payment purposes, the receipt of approval by the applicable Governmental Authority with respect to such price. 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 7 of 45 

 “Prior Collaboration Agreement” means that certain Collaboration
Agreement by and between Seller and Buyer, dated August 23, 2007, as previously amended on or about November 24, 2008, June 29, 2009, and October 12, 2009, which was amended, restated, and superseded by the Amended and
Restated Collaboration Agreement. 
 “Product” means any products containing glyceryl
tri-(4-phenylbutyrate) (including any analogs, metabolites, prodrugs, salts, isomers, enantiomers and other physical forms and derivatives thereof). 

“Product Marks” means the trademarks set forth on Schedule 2.01(d). 

“Product Records” means to the extent permitted by Law, all books and records necessary for, or prepared for the purpose
of, the research, development, or commercialization (but not manufacture) of Product, including all clinical and preclinical reports, laboratory notebooks, patent prosecution files for the HPN-100 Patents,
copies of all supplier lists, marketing studies, consultant reports, physician databases, and correspondence with respect to the Product to the extent maintained by Seller, all reports to and correspondence with the FDA, exception reports and
investigations, specifications for raw materials and FDA communication thereon, communication relating to manufacturing or packaging with any of the FDA, vendors or suppliers, and all complaint files and adverse event files with respect to the
Product, provided, however, that (a) Seller may retain, to the extent in Seller’s possession a copy of any such books and records to the extent necessary for Tax, accounting, litigation or regulatory or reporting
requirements, and (b) any attorney work product, attorney-client communications and other items protected by privilege that are held by Seller shall be excluded. For the avoidance of doubt, while the Product Records include any and all INDs and
NDAs for Product (including any portions thereof that reference any data, reports, studies, or study results for Buphenyl), Product Records does not include the original books and records for any such data, reports, studies, or study results for
Buphenyl that were generated by Seller prior to August 23, 2007 (which instead are part of the UCD Data). 
 “Product
Registrations” means (a) the approvals or registrations which have been received by the Seller and its Affiliates, for the investigation, clinical testing, sale, distribution and/or marketing of Product, and any applications
therefor (including any NDAs and INDs), including those approvals and registrations set forth on Schedule 2.01(d), and (b) all dossiers, reports, data and other written materials filed by Seller and its Affiliates (or by Buyer on behalf
of Seller or its Affiliates prior to the Signing Date) as part of such approvals, registrations, or applications. 
 “Product
Rights” has the meaning set forth in Section 2.01. 
 “Purchase Price” has the
meaning set forth in Section 2.05(e). 
 “Representative” means, with respect to any Person,
any and all directors, officers, employees, consultants, financial advisors, counsel, accountants and other agents of such Person. 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 8 of 45 

 “Restricted Business” means developing, marketing, promoting,
manufacturing, selling, offering to sell, distributing, importing, or otherwise commercializing an Active Moiety Product for the treatment of UCD or HE (other than parenteral usage in HE). 

“Restricted Period” has the meaning set forth in Section 7.02(a). 

“Rules” has the meaning set forth in Section 10.10(b)(i). 

“SDEA” has the meaning set forth in Section 7.11. 

“Seller” has the meaning set forth in the preamble. 

“Seller Basket Exclusions” has the meaning set forth in Section 8.05(b) 

“Seller Indemnitees” has the meaning set forth in Section 8.04. 

“Signing Date” has the meaning set forth in the preamble. 

[***]. 
 “[***] Orphan
Designations” means (a) the orphan drug designation, dated [***], granted by the FDA to Seller for Product for [***]; (b) the orphan drug designation, dated [***], granted by the FDA to Seller for Buphenyl for [***]; and
(c) any other orphan drug designation granted by the FDA to Seller or its Affiliates for [***]. 
 “Summar
Agreement” means the agreement by and between Seller (as successor in interest to Medicis) and Dr. Marshall L. Summar, dated April 1, 2002. 

“Taxes” means all federal, state, local, foreign and other income, gross receipts, sales, use, value added, production,
ad valorem, transfer, documentary, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or
personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such
additions or penalties. 
 “Tax Return” means any return, declaration, report, claim for refund, information return or
statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof. 

“Technology Assignment Agreement” has the meaning set forth in Section 3.02(a)(iii). 

“Third Party” means any Person that is not a Party or an Affiliate of a Party. 

“Third Party Claim” has the meaning set forth in Section 8.06(a). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 9 of 45 

 “Transaction Documents” means this Agreement, the Bill of Sale, the
Assignment and Assumption Agreement, Technology Assignment Agreement, the Amended and Restated Collaboration Agreement, the mutual release, and the other agreements, instruments and documents required to be delivered at the Closing. 

“UCD” means urea cycle disorder. 

“UCD Data” has the meaning set forth in Section 4.01(c)(i). 

“UCD Products” means any products being developed or commercialized by a Seller or a Seller Affiliate for the
treatment of UCD, including Buphenyl and Ammonul. 
 “Ucyclyd Manufacturing
Know-How” means (a) any and all Know-How for the manufacture or supply of Product that (i) was developed or acquired by Seller prior to
August 23, 2007 and is owned by Seller as of the Signing Date, or (ii) as of the Signing Date, is in-licensed by Seller to the extent licensable to Buyer; and (b) any and all intellectual
property rights in or to any of the foregoing (other than Patents) as of the Signing Date. Notwithstanding the foregoing, Ucyclyd Manufacturing Know-How does not include any method of treatment, packaging,
drug delivery, composition, formulation or dosage unit of Product, but does include any processes for manufacturing or supplying the method of treatment, packaging, drug delivery, composition, formulation or dosage unit of Product that (i) was
developed or acquired by Seller prior to August 23, 2007 and is owned by Seller as of the Signing Date, or (ii) as of the Signing Date, is in-licensed by Seller to the extent licensable to Buyer.

 “Ucyclyd Manufacturing Patents” means any and all Patents arising out of the Ucyclyd Manufacturing Know-How. 
 “Ucyclyd Manufacturing Technology” means Ucyclyd Manufacturing Patents
and Ucyclyd Manufacturing Know-How. 
 ARTICLE II 

PURCHASE AND SALE 

Section 2.01 Purchase and Sale of Assets. Subject to the terms and conditions set forth herein, at the
Closing, Seller shall sell, assign, transfer, convey and deliver to Buyer, and Buyer shall purchase from Seller, free and clear of any Liens other than Permitted Encumbrances, all of Seller’s rights, title and interests in and to Product (which
shall include the Assets, but shall exclude the Excluded Assets) (collectively, the “Product Rights”). For purposes of this Agreement, the “Assets” means the following: 

(a)     all Product Registrations, both inside the United States and outside the United States, including those Product
Registrations set forth on Schedule 2.01(a); 
 (b)     the Hyperion Manufacturing Technology; 

(c)     the HPN-100 Technology, including those Patents that are set forth on
Schedule 2.01(c); 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 10 of 45 

 (d)    those trademarks, design marks, service marks, and/or trade
names, whether registered or not, that are set forth on Schedule 2.01(d), including all registrations and applications therefor; 

(e)    those contracts that are set forth on Schedule 2.01(e) (the “Assigned Contracts”); 

(f)    the Product Records; 

(g)    all rights to any Actions of any nature available to or being pursued by Seller to the extent related to the
Business, the Product Rights, or the Assumed Liabilities, whether arising by way of counterclaim or otherwise; and 

(h)    all of Seller’s rights under warranties, indemnities and all similar rights against Third Parties to the
extent related to any Product Rights. 
 Section 2.02 Excluded Assets. Notwithstanding the foregoing, the
Product Rights shall not include the following assets (collectively, the “Excluded Assets”): 

(a)    All contracts to which Seller or an Affiliate are a party other than Assigned Contracts (the “Excluded
Contracts”); 
 (b)    the Ucyclyd Manufacturing Technology (which is licensed to Buyer pursuant to
Section 4.01(a) of this Agreement) and the [***] Orphan Designations; and 
 (c)    the rights which accrue or will
accrue to Seller under the Transaction Documents. 
 Section 2.03 Assumed Liabilities. Subject to the terms and
conditions set forth herein, Buyer shall assume and agree to pay, perform and discharge only the following Liabilities of Seller (collectively, the “Assumed Liabilities”), and no other Liabilities: 

(a)    all Liabilities arising out of or relating to any clinical trial liability, product liability, breach of warranty
or similar claim for injury to person or property that resulted from (i) the use or misuse of the Product sold or used on or after the Closing or (ii) the use or misuse of Product in connection with the activities conducted by Buyer prior
to the Closing (including under the Prior Collaboration Agreement), except to the extent directly caused by (i) the failure by Seller or any of its Affiliates to comply with any Law or Governmental Order or (ii) Seller’s failure to
perform its obligations under this Agreement or the Prior Collaboration Agreement; 
 (b)    all Liabilities arising out
of or relating to any activities or obligations undertaken by Buyer under or in connection with the Prior Collaboration Agreement (including the activities and obligations under the Development and Regulatory Program (as defined in the Prior
Collaboration Agreement)), which Buyer acknowledges includes all such activities prior to, on and after the Signing Date; 

(c)    all Liabilities arising out of or relating to any contracts into which Buyer entered or otherwise is a party in
connection with the activities undertaken by Buyer under or in connection with the Prior Collaboration Agreement (including the activities under the Development and Regulatory Program), which Buyer acknowledges includes all such activities prior to,
on and after the Signing Date; 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 11 of 45 

 (d)    any Liabilities arising out of, in respect of or in connection
with the failure to comply with any Law or Governmental Order to the extent arising out, or resulting from, Buyer’s acts, omissions or direction, including Buyer’s acts, omissions or directions as regulatory sponsor for the Product under
the Prior Collaboration Agreement; 
 (e)    all Liabilities associated with the Product Registrations, including the
responsibility for all product development, testing, complaints, recalls, adverse event reporting, market withdrawals and field corrections of the Product to the extent that the same relate to Product sold on or after the Closing, except to the
extent directly caused by (i) the failure by Seller or any of its Affiliates to comply with any Law or Governmental Order or (ii) Seller’s failure to perform its obligations under this Agreement or the Prior Collaboration Agreement;

 (f)    all Liabilities for Taxes arising out of or relating to, directly or indirectly, the Product Rights (including
the Product), or the ownership, sale or lease of any of the Product Rights, other than the Liabilities for Taxes set forth in Section 2.04(f); 

(g)    the Assumed Payments; and 

(h)    all Liabilities in respect of the Assigned Contracts but only to the extent that such Liabilities thereunder
(i) are required to be performed after the Signing Date, were incurred in the ordinary course of business and do not relate to any failure to perform, improper performance, warranty or other breach, default or violation by Seller on or prior to
the Closing, or (ii) relate to any failure to perform, improper performance, warranty or other breach, default or violation, in each case by Buyer on or prior to the Closing (including on or prior to the Signing Date), directly or indirectly,
of the terms, conditions, covenants, representations, warranties or other provisions of an Assigned Contract. 

Section 2.04 Excluded Liabilities. Notwithstanding the provisions of Section 2.03
or any other provision in this Agreement to the contrary, Buyer shall not assume and shall not be responsible to pay, perform or discharge any Liabilities of Seller or any of its Affiliates of any kind or nature whatsoever other than the Assumed
Liabilities (the “Excluded Liabilities”). Seller shall, and shall cause its Affiliates to, pay and satisfy in due course all Excluded Liabilities which they are obligated to pay and satisfy. Without limiting the generality of the
foregoing, the Excluded Liabilities shall include the following: 
 (a)    all Liabilities arising out of or relating to
any product liability, breach of warranty or similar claim for injury to person or property which are directly caused by the use or misuse of the Product by Seller or its Affiliates on or prior to the Signing Date (other than Liabilities resulting
from those activities conducted by Buyer prior to the Closing, including activities conducted by Buyer under the Prior Collaboration Agreement); 

(b)    any Liabilities in respect of any pending or threatened Action arising out of, relating to or otherwise in respect
of the Business or the Product Rights, to the extent such Action is directly caused by Seller or its Affiliates on or prior to the Signing Date (other than Liabilities resulting from those activities conducted by Buyer prior to the Closing,
including activities conducted by Buyer under the Prior Collaboration Agreement); 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 12 of 45 

 (c)    any Liability of Seller or any of its Affiliates arising out of
or relating to any Excluded Asset; 
 (d)    any Liability of Seller or any of its Affiliates for their accounts
payable, including those which constitute intercompany payables owing to Affiliates of Seller, incurred in connection with the Product before the Closing and for which Seller is responsible under this Agreement or the Prior Collaboration Agreement;

 (e)    any Liabilities of Seller arising or incurred in connection with the negotiation, preparation, investigation
and performance of this Agreement, the other Transaction Documents and the transactions contemplated hereby and thereby, including fees and expenses of counsel, accountants, consultants, advisers and others, in all cases except to the extent such
fees and expenses are the responsibility of Buyer under this Agreement or the other Transaction Documents; 
 (f)    any
Liability for Taxes of Seller (or any stockholder or Affiliate of Seller) or relating to the Business, the Product Rights or the Assumed Liabilities for any Pre-Closing Tax Period; 

(g)    any Liabilities under the Excluded Contracts, (i) which are not validly and effectively assigned to Buyer
pursuant to this Agreement; or (ii) to the extent such Liabilities arise out of or relate to a breach by Seller of such Excluded Contracts prior to Closing; 

(h)    any Liabilities arising out of, in respect of or in connection with the failure by Seller or any of its Affiliates
to comply with any Law or Governmental Order that does not otherwise arise as a result of Buyer’s acts, omissions or direction, including Buyer’s acts, omissions or directions as regulatory sponsor for the Product under the Prior
Collaboration Agreement; and 
 (i)    except to the extent specifically provided in
Section 2.03, any and all other Liabilities, obligations and commitments of whatever kind and nature, primary or secondary, direct or indirect, absolute or contingent, known or unknown, whether or not accrued, arising out
of or relating to, directly or indirectly, the Product Rights (including the Product) but only to the extent related to any period before the Closing. 

Section 2.05 Purchase Price. 

(a)    Up-front Payment. The
up-front payment for the Product Rights is six million dollars ($6,000,000) (the “Initial Purchase Price”), plus the assumption of the Assumed Liabilities. Within [***] following the Closing,
Buyer shall make the payment of the Initial Purchase Price via wire transfer in immediately available funds to an account designated by Seller prior to the Closing. 

(b)    Other Payments. In addition, Buyer shall be obligated to make the regulatory milestone payments, net sales
milestone payments, and other ongoing payments (except for royalties as described in Section 2.05(c)), in each case that are provided in Schedule 2.05(b) (the “Contingent Payments”). For clarity,
Buyer will not be required to make any regulatory or sales milestone payments hereunder for sales or development of Product in UCD. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 13 of 45 

 (c)    In addition, Buyer shall be obligated to make the royalty
payments set forth in Section 3 of Schedule 2.05(b) in consideration for the license granted by Seller under Section 4.01(a) with respect to Ucyclyd Manufacturing Technology. 

(d)    Assumed Payment Obligations. In addition to the payments otherwise payable to Seller under this Agreement,
as of the Signing Date, Buyer hereby assumes the payment obligations to the applicable Persons as set forth in Section 4 of Schedule 2.05(b) (“Assumed Payments”). Buyer agrees to pay the Assumed
Payments as provided in Schedule 2.05(b). 
 (e)    No Other Payments. Notwithstanding anything to the
contrary set forth in the Prior Collaboration Agreement, the payments set forth in Sections 2.05(a), (b), and (d) and in Schedule 2.05(b) (except royalty payments under Section 3 of
Schedule 2.05(b)) (collectively, the “Purchase Price”), together with the royalty payments under Section 3 of Schedule 2.05(b), constitute Buyer’s total payment obligations in connection
with the purchase of the Product Rights. Without limiting the generality of the foregoing, the $[***] payment set forth in the Prior Collaboration Agreement for FDA acceptance of filing of an NDA for Product in UCD shall not be due. Except as
expressly set forth in the Agreement, the Parties shall have no obligation under the Agreement to pay or reimburse the other Party for any other amounts, including any other costs or expenses incurred by the other Party in connection with the
performance of its obligations under the Agreement. This provision shall in no way limit a Party’s ability to collect damages for any breach by the other Party or in any way limit a Party’s indemnification obligations under the Agreement.

 Section 2.06 Financial Audit and Record-Keeping Requirements. The Parties shall comply with the audit
and record-keeping requirements set forth on Schedule 2.06. 
 Section 2.07 Withholding Tax. Buyer
shall be entitled to deduct and withhold from the Purchase Price all Taxes that Buyer may be required to deduct and withhold under applicable Law. All such withheld amounts shall be treated as delivered to Seller hereunder, provided that Buyer gives
Seller prompt written notice of the obligation to withhold such Taxes, and upon written request of Seller, Buyer shall provide to Seller evidence of such obligation. Upon reasonable written request of Seller, and before the date any payments are
due, Buyer shall cooperate with Seller in preparing and delivering to the relevant Governmental Authorities any documentation necessary to enable reduced rates of withholding Tax set forth in any applicable Law to apply to such payments, and shall
provide any further documentation or certifications as may be reasonably required or helpful to achieve such reduced rates. 

Section 2.08 Third Party Consents. To the extent that Seller’s rights under any Assigned Contract that
is part of the Product Rights may not be assigned to Buyer without the consent of another Person which has not been obtained, this Agreement shall not constitute an agreement to assign the same if an attempted assignment would constitute a breach
thereof or be unlawful, and Seller, at its expense, shall use its commercially reasonable efforts to obtain any such required consent(s) as promptly as possible. In the case of assignment of the Brusilow License Agreement hereunder, the Parties
agree that “commercially reasonable efforts” shall not require the Seller to pay to the Brusilow Parties, as a condition of obtaining consent therefrom 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 14 of 45 

 
for such assignment, any amounts not otherwise due to the Brusilow Parties. If any such consent shall not be obtained or if any attempted assignment would be ineffective or would impair
Buyer’s rights under the portion of the Product Rights in question so that Buyer would not in effect acquire the benefit of all such rights, Seller, to the maximum extent permitted by Law, shall use commercially reasonable efforts after the
Closing to obtain for Buyer the benefits thereunder and shall reasonably cooperate, to the maximum extent permitted by Law, with Buyer in any other reasonable arrangement designed to provide such benefits to Buyer. Notwithstanding any provision in
this Section 2.08 to the contrary, in the event Seller is unable to obtain consent to assign the Brusilow License Agreement, Seller shall be deemed to have granted an exclusive sublicense to the rights under the Brusilow
License Agreement without additional payment, which licenses shall be [***] by Seller ([***] hereof) unless and until such consent to assignment is obtained and the applicable agreement is assigned to Buyer. 

ARTICLE III 

CLOSING 

Section 3.01 Closing. The consummation of the transactions contemplated by this Agreement (the
“Closing”) shall take place on the Signing Date. 
 Section 3.02 Closing Deliverables.

 (a)    At the Closing, Seller shall deliver to Buyer the following: 

(i)    a bill of sale in the form of Exhibit A hereto (the “Bill of Sale”) and duly executed by
Seller, transferring to Buyer the tangible personal property included in the Product Rights; 
 (ii)    an assignment
and assumption agreement in the form of Exhibit B hereto (the “Assignment and Assumption Agreement”) and duly executed by Seller, effecting the assignment to and assumption by Buyer of the Assigned Contracts; 

(iii)    a technology assignment agreement in the form of Exhibit C hereto (the “Technology Assignment
Agreement”) and duly executed by Seller, transferring all of Seller’s right, title and interest in and to the HPN-100 Technology to Buyer; 

(iv)     a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Seller certifying that
attached thereto are true and complete copies of all resolutions adopted by the board of directors of Seller authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the
transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby; 

(v)     a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Seller certifying the names
and signatures of the officers of Seller authorized to sign 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 15 of 45 

 
this Agreement, the Transaction Documents and the other documents to be delivered hereunder and thereunder; and 

(vi)    a copy of Seller’s FDA Transfer of Ownership Letter, executed by Seller. 

(b)    At the Closing, Buyer shall deliver to Seller the following: 

(i)    the Assignment and Assumption Agreement duly executed by Buyer; 

(ii)    a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Buyer certifying that attached
thereto are true and complete copies of all resolutions adopted by the board of directors of Buyer authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions
contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby; 

(iii)    a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Buyer certifying the names
and signatures of the officers of Buyer authorized to sign this Agreement, the Transaction Documents and the other documents to be delivered hereunder and thereunder; and 

(iv)    a copy of Buyer’s FDA Transfer of Ownership Letter, executed by Buyer. 

ARTICLE IV 

OTHER RIGHTS AND LICENSES 

Section 4.01 Licenses to Buyer 

(a)    Post Closing. On and after the Signing Date, subject to the terms and conditions of this Agreement, Seller
hereby grants to Buyer a worldwide, perpetual, [***], exclusive (even as to Seller), sublicenseable (through multiple tiers), fee-earning license, under the Ucyclyd Manufacturing Technology and, unless and
until it is assigned to Buyer pursuant to the Amended and Restated Collaboration Agreement, the Marketed Products Technology, to research, develop, make, have made, import, use, sell and offer for sale Products. 

(b)    Ex-US Clinical Trial Rights. 

(i)    Buyer acknowledges and agrees that, prior to the Signing Date, Seller has granted distribution rights for Buphenyl
to certain Third Parties in the specific countries listed on Schedule 4.01(b) (the “Distributor Territories”). 

(ii)    During the Marketed Products Pre-Closing Period, Seller will work with
Buyer and [***] to facilitate [***] (and, if necessary, obtain the [***]) in the [***], as follows: prior to [***] of [***], Buyer shall notify Seller in writing of the [***] within [***] in which Buyer in good faith intends to [***]. Upon receipt
of such written notice, Seller shall provide Buyer with (A) the 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 16 of 45 

 
[***] necessary for Buyer to determine the [***] set forth below in [***], and (B) a good faith estimate of the [***] that are receiving [***] in such [***]. 

(iii)    Buyer shall [***] Seller for any [***] during the Marketed Products
Pre-Closing Period due to [***] in any of [***] conducted outside of [***] in the [***]. Such [***] will be calculated as [***] (A) [***], and (B) [***]; provided, however, that the [***]. 

(iv)    Any [***] under this Section 4.01(b) shall be made within [***] after delivery of a
written invoice to Buyer that details the calculation of the [***] by Buyer. During the Marketed Products Pre-Closing Period and for [***] thereafter, Buyer will have a [***] audit right to confirm the [***]
claimed by Seller hereunder. In connection with such audit, the Parties shall comply with the audit and record-keeping requirements set forth on Schedules 2.05(b) and 2.06. 

(v)    For the avoidance of doubt, nothing in this Section 4.01(b) shall apply to, or otherwise
restrict Buyer from [***] (A) in a [***], (B) in the [***], or (C) in all other [***] other than those included within the [***]. 

(c)    Rights of Reference. 

(i)    On and after the Signing Date and until the end of the Marketed Products
Pre-Closing Period, Seller hereby grants to Buyer a limited, [***], non-exclusive, non-transferable (except as permitted by
Section 10.07) right to use and reference any and all data developed or controlled by Seller for UCD Products through the date of FDA approval of the Product Registration for the Product described in the application that
Buyer submitted to FDA for Product Registration as of the Signing Date (“UCD Data”), including any toxicology, pre-clinical, clinical and safety data and other data contained in any regulatory
filings for such UCD Products. In the event that Buyer exercises the option to purchase the Marketed Product Rights pursuant to the Amended and Restated Collaboration Agreement, then the UCD Data will be assigned to Buyer as part of the Marketed
Product Rights (along with any other data that is part of the Marketed Product Rights) on the terms set forth therein, subject to the right of Seller and its Affiliates to use and reference the UCD Data solely for any products as to which Seller and
its Affiliates are not otherwise restricted pursuant to Section 7.02 hereof. In the event that Buyer does not exercise the option to purchase the Marketed Products Rights pursuant to the Amended and Restated Collaboration
Agreement (or the assignment of Marketed Products Rights thereunder is otherwise not consummated), Buyer shall, after the end of the Marketed Products Pre-Closing Period, retain the right to use and reference
the UCD Data solely to the extent necessary to [***] for the [***]. For the avoidance of doubt, nothing herein shall prohibit Buyer from referencing any data that Buyer would otherwise be permitted to reference under applicable Law. 

(ii)    On and after the Signing Date, Seller hereby grants to Buyer a limited, [***], perpetual, non-exclusive, non-transferrable (except as permitted by Section 10.07) right to use and reference, with respect to development of products for UCD
and HE (other than parenteral usage in HE), any and all data (other than UCD Data) developed or controlled by Seller or its Affiliate as of the Signing Date with respect to any Active Moiety Product. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 17 of 45 

 (d)    Formulation Technology. To the extent that the
development efforts of or on behalf of Seller or its Affiliates (but excluding any efforts by a Person during any period when it is not an Affiliate of Seller) relating to an Active Moiety Product results in a [***] technology or other formulation
technology that may be useful to Buyer’s efforts with respect to (i) Product in UCD or HE, or (ii) if Buyer exercises the option to purchase the Marketed Products Rights, Buphenyl for UCD, then Seller hereby grants to Buyer a non-exclusive, [***], perpetual, worldwide, royalty-bearing license, under such technology or any intellectual property in or covering such technology (but excluding any intellectual property developed by a Person
during any period when it is not an Affiliate of Seller), to use and practice such technology in connection with the research, development, manufacturing, and/or commercialization of Product in UCD and HE and Buphenyl for the treatment of UCD, which
license shall be automatically effective, on a product-by-product basis, upon Buyer’s notice to Seller that Buyer desires to practice such license. In the event
that Seller, directly or indirectly, is the subject of a Change in Control, the foregoing rights and licenses shall not include any [***] technology or other formulation technology that was owned or
in-licensed by the acquiring entity (or any Affiliate thereof, other than Seller) prior to the acquisition or that is developed by the acquiring entity (or any Affiliate thereof) independently following the
Change in Control. To the extent that Buyer exercises its right to practice such license, Buyer shall pay a royalty of [***] percent ([***]%) on Net Sales of any products utilizing the licensed technology. The payment of such royalties shall be
governed by the payment, reporting, and audit provisions set forth in Schedules 2.05(b) and 2.06. For purposes of calculating the royalty due under this subsection (d), the definition of Net Sales in Schedule 2.05(b) shall be used
except that any references to “Product” therein also shall include any product for which a royalty is due under this Section.  

Section 4.02 Licenses to Seller. 

(a)    Buyer hereby grants Seller and its Affiliates the option to purchase the right to use and reference, for the
development, marketing approval and commercialization of any product to treat [***] (and/or those other indication(s) requested by Seller and/or its Affiliates and approved by Buyer as provided below), any and all data developed or controlled by
Buyer and its Affiliates as of the Signing Date with respect to Product or any other Active Moiety Product (“Buyer Product Data”). For clarity, the foregoing is not intended to grant Seller or its Affiliates any rights to develop or
commercialize Product. The option will be exercisable in writing any time after the Signing Date and until the end of the Marketed Products Pre-Closing Period. Prior to exercising such option (and prior to the
end of the Marketed Products Pre-Closing Period) and for the purpose of determining whether referencing the Buyer Product Data in connection with such product will be acceptable to the FDA, Seller shall be
permitted to disclose to the FDA, as part of [***] for a product covered by this subsection (a), a summary of [***], which summary will have a level of detail sufficient to permit FDA to determine whether Seller may use the Buyer Product Data
in connection with such product. At Seller’s reasonable request, Buyer shall cooperate with Seller to prepare such summary (including providing any additional detail that may be requested by FDA prior to or following [***] to enable FDA to
determine whether Seller may use the Buyer Product Data in connection with such product), and in any event the final content of any such summary shall be subject to the written approval of 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 18 of 45 

 
Buyer prior to submission to the FDA, which approval shall not be unreasonably withheld or delayed. 

(b)    If Seller or an Affiliate exercises the option set forth in subsection (a) above, Buyer hereby grants
Seller and its Affiliates , subject to the terms and conditions of this Agreement, a non-exclusive, sublicenseable (through multiple tiers), [***], perpetual, worldwide license, under any intellectual property
rights (i) owned by Buyer, or (ii) in-licensed by Buyer to the extent licensable to Seller and its Affiliates, to develop, have developed, make, have made, sell, have sold, offer to sell, import,
use, have used, practice and have practiced one or more Active Moiety Product (other than Product), anywhere in the world, solely for the treatment of [***]. For the avoidance of doubt, no rights are granted under this subsection
(b) with respect to any indication other than [***]. In the event that Buyer, directly or indirectly, is the subject of a Change in Control, the foregoing license shall not include any Patents or
Know-How that was owned or in-licensed by the acquiring entity (or any Affiliate thereof, other than Buyer) prior to the acquisition or that is developed by the
acquiring entity (or any Affiliate thereof) independently of the Business following the Change in Control. The foregoing license shall not include a sublicense under the Brusilow License Agreement unless Seller and its Affiliates agree in writing to
pay (in addition to any amounts due under subsection (d) below) any royalties that would be due under the Brusilow License Agreement on account of sales of the applicable Active Moiety Product by Seller, its Affiliates, or their
sublicensees. 
 (c)    After exercise of the option set forth in subsection (a) above, Seller and its
Affiliates shall have the right to request the right to reference the Buyer Product Data for additional indications (other than those precluded by the restrictive covenants in Section 7.02) for which Seller or an Affiliate
has [***] (“New Indications”). Any New Indication shall be subject to written approval by Buyer; provided, however, that Buyer shall only be permitted to withhold such approval if [***]. Any request to include a New
Indication shall be accompanied by [***]. If Buyer approves a New Indication, Buyer shall disclose to Seller or the requesting Affiliate, in confidence, such patent rights that are owned or controlled by Buyer and its Affiliates and that Buyer
believes are reasonably likely to cover the making, having made, selling, offering to sell, using and/or practicing of the applicable product(s) in the New Indication (based on information about such product and New Indication provided by Seller or
its Affiliate), and the Parties shall discuss in good faith the applicability of such patent rights to such product and shall discuss in good faith a non-exclusive, field-limited license to Seller and its
Affiliates under such patents with respect to such product on commercially reasonable terms and conditions. In the event that Buyer withholds its approval of a New Indication, Buyer shall specify the basis for such
non-approval in writing to Seller or its applicable Affiliate. 
 (d)    If
Seller exercises the option set forth in subsection (a) above, Seller will pay Buyer (i) a one-time payment of $[***] within [***] following the exercise of the option (which if exercised on
or before the Signing Date will be set off against the $6 million due from Buyer pursuant to Section 2.05(a), leaving a $[***] payment from [***]) and (ii) a one-time
payment of $[***] no later than [***] after the first approval of any NDA (for any indication) in the United States or any Major Non-U.S. Territory that includes or references the Buyer Product Data. In
addition, Seller will pay Buyer a royalty of [***]% of Net Sales (as defined in Schedule 2.05(b), applied mutatis mutandis) of products for any New Indication; provided, however, that

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 19 of 45 

 
aggregate, lifetime royalty payments to Buyer under this sentence shall not exceed $[***]. The payment of such royalties shall be governed by the payment, reporting, and audit provisions set
forth in Schedules 2.05(b) and 2.06. 
 Section 4.03 Retained
Know-How. Nothing in this Agreement or the Amended and Restated Collaboration Agreement shall preclude the employees or contractors of either Party or their respective Affiliates from using Know-How that is retained in their unaided memories. As used herein, “unaided memory” means that the applicable employee or contractor did not intentionally memorize the
Know-How for the purpose of appropriating the Know-How and subsequently using or disclosing it. Nothing in this Section 4.03 shall be deemed to
grant to either Party a license under the other Party’s patents or copyrights. 
 Section 4.04 Covenant Not to
Assert. Seller and Medicis each agrees, effective as of the Signing Date, that neither it nor any of its Affiliates shall assert or attempt to enforce against Buyer, its Affiliates, or any of its or their licensees, sublicensees, or distributors
of a Product (each, a “Buyer Party”), any intellectual property right owned or licensed by Seller or Medicis, or any of their respective Affiliates (including any intellectual property owned or licensed by successors or assigns of
Seller, Medicis or their respective Affiliates that is based on an intellectual property right owned or licensed by Seller, Medicis or their respective Affiliates), as of the Signing Date or thereafter, with respect to the development, use, making,
having made, importing, selling, or offering for sale by or on behalf of a Buyer Party anywhere in the world an Existing Product for the Existing Product Indications. For clarity, this Section 4.04 extends to any successors
or assigns of a Buyer Party and is binding on the successors and assigns of Seller, Medicis and their respective Affiliates. 

Section 4.05 No Contest. 

(a)    On and following the Closing, neither Seller nor Medicis shall directly or indirectly, individually, or in
association or in combination with any other Person, attack or contest the validity, enforceability, status, registration of, or Buyer’s ownership of, or right in or to the HPN-100 Technology as it
existed as of the Signing Date, nor shall Seller or Medicis willingly become an adverse party to Buyer (or any licensors of the HPN-100 Technology, if applicable) in any action contesting the validity,
enforceability, status or registration of, or any of its (or their) ownership of or rights in, the HPN-100 Technology as it existed as of the Signing Date, as the case may be. 

(b)    On and following the Signing Date, Buyer shall not directly or indirectly, individually, or in association or in
combination with any other Person, attack or contest the validity, enforceability, status, registration of, or Seller’s, Medicis, or their respective Affiliates’ ownership of, or right in or to the Ucyclyd Manufacturing Technology as it
existed as of the Signing Date, nor shall Buyer willingly become an adverse party to Seller, Medicis or any of their respective Affiliates (or any licensors of the Ucyclyd Manufacturing Technology, if applicable) in any action contesting the
validity, enforceability, status or registration of, or any of its (or their) ownership of or rights in, the Ucyclyd Manufacturing Technology as it existed as of the Signing Date, as the case may be. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 20 of 45 

 Section 4.06 Mutual Release. The Parties acknowledge that
they have both executed the mutual release attached here to as Exhibit D, effective as of the Signing Date. 
 ARTICLE V 

REPRESENTATIONS AND WARRANTIES OF SELLER 

Except as set forth in the correspondingly numbered Section of the Disclosure Schedules, Seller represents and warrants to Buyer that the
statements contained in this Article V are true and correct as of the Signing Date. 
 Section 5.01
Organization of Medicis and Seller. 
 (a)    Medicis is a corporation duly organized, validly existing and in
good standing under the Laws of the state of Delaware. 
 (b)    Seller is a corporation duly organized, validly
existing and in good standing under the Laws of the state of Maryland. Seller has full corporate power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on the Business as currently
conducted. 
 Section 5.02 Authority of Medicis and Seller. 

(a)    Medicis has full corporate power and authority to enter into this Agreement, to carry out its obligations hereunder
and to consummate the transactions contemplated hereby. The execution and delivery by Medicis of this Agreement, the performance by Medicis of its obligations hereunder and the consummation by Medicis of the transactions contemplated hereby have
been duly authorized by all requisite corporate action on the part of Medicis. This Agreement has been duly executed and delivered by Medicis, and (assuming due authorization, execution and delivery by Buyer) this Agreement constitutes a legal,
valid and binding obligation of Medicis enforceable against Medicis in accordance with its terms except as enforcement may be limited by general principles of equity (regardless of whether such enforceability is considered in a proceeding at law or
in equity) and the effect of applicable bankruptcy, insolvency, moratorium and other similar Laws of general application relating to or affecting creditors’ rights generally, including the effect of statutory or other Laws regarding fraudulent
conveyances and preferential transfers. 
 (b)    Seller has full corporate power and authority to enter into this
Agreement and the other Transaction Documents to which Seller is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Seller of this
Agreement and any other Transaction Document to which Seller is a party, the performance by Seller of its obligations hereunder and thereunder and the consummation by Seller of the transactions contemplated hereby and thereby have been duly
authorized by all requisite corporate action on the part of Seller. This Agreement has been duly executed and delivered by Seller, and (assuming due authorization, execution and delivery by Buyer) this Agreement constitutes a legal, valid and
binding obligation of Seller enforceable against Seller in accordance with its terms except as enforcement may be limited by general 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 21 of 45 

 
principles of equity (regardless of whether such enforceability is considered in a proceeding at law or in equity) and the effect of applicable bankruptcy, insolvency, moratorium and other
similar Laws of general application relating to or affecting creditors’ rights generally, including the effect of statutory or other Laws regarding fraudulent conveyances and preferential transfers. When each other Transaction Document to which
Seller is or will be a party has been duly executed and delivered by Seller (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of Seller
enforceable against Seller in accordance with its terms except as enforcement may be limited by general principles of equity (regardless of whether such enforceability is considered in a proceeding at law or in equity) and the effect of applicable
bankruptcy, insolvency, moratorium and other similar Laws of general application relating to or affecting creditors’ rights generally, including the effect of statutory or other Laws regarding fraudulent conveyances and preferential transfers.

 Section 5.03 No Conflicts; Consents. 

(a)     The execution, delivery and performance by Medicis of this Agreement, and the consummation of the transactions
contemplated hereby and thereby, do not and will not: (i) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other
organizational documents of Medicis; (ii) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Medicis, the Product, or the Product Rights; (iii) require the consent, notice or
other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in
any party the right to accelerate, terminate, modify or cancel any contract or Product Registration to which Medicis is a party or by which Medicis is bound or to which any of the Product Rights are subject (including any Assigned Contract); or
(iv) result in the creation or imposition of any Lien other than Permitted Encumbrances on the Product Rights. No consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by
or with respect to Medicis in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby and thereby, except for notice with respect to any Product Registrations transferred to Buyer.

 (b)    The execution, delivery and performance by Seller of this Agreement and the other Transaction Documents to
which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (i) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation,
bylaws or other organizational documents of Seller; (ii) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Seller, the Product, or the Product Rights; (iii) require the
consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the
acceleration of or create in any party the right to accelerate, terminate, modify or cancel any contract or Product Registration to which Seller is a party or by which Seller is bound or to which any of the Product Rights are subject

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 22 of 45 

 
(including any Assigned Contract); or (iv) result in the creation or imposition of any Lien other than Permitted Encumbrances on the Product Rights. No consent, approval, Permit,
Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Seller in connection with the execution and delivery of this Agreement or any of the other Transaction Documents and the
consummation of the transactions contemplated hereby and thereby, except for notice with respect to any Product Registrations transferred to Buyer. 

Section 5.04 Title to Assets. 

(a)    Seller owns good and marketable title to all of the Assets, free and clear of any and all Liens. Notwithstanding the
foregoing, Buyer acknowledges and agrees that Buyer has been operating the Business exclusively since August 23, 2007 and that Seller shall have no Liabilities with respect to any Liens or other adverse effect on title to the Assets resulting
from Buyer’s operation of the Business. 
 (b)    Medicis and its Affiliates (other than Seller) have assigned any
and all of their rights and interests in and to all of the Assets to Seller. 
 Section 5.05 No Third Party
Rights. Seller has not granted any rights to any Third Party to develop, research, manufacture, sell or distribute the Product. 

Section 5.06 HPN-100 Patents. Except for those issued and
unexpired patents and pending patent applications requested, filed, prosecuted or otherwise prepared by or on behalf of Hyperion, Section 5.06 of the Disclosure Schedules contain a correct and complete list of all of the
other issued and unexpired patents and pending patent applications with respect to the manufacture, sale or use of Product and which are owned by, or in-licensed to, Seller or its Affiliates. 

Section 5.07 Brokers. Neither Seller nor any officer, director or agent of Seller has employed any
broker, finder, nor agent with respect to the Agreement or the transactions contemplated hereby. 
 Section 5.08
No Licenses or Liens. (a) Neither Seller nor its Affiliates has assigned any rights to the HPN-100 Technology or the Brusilow License Agreement, and neither Seller nor its Affiliates have
sublicensed or granted to any Third Party any (i) exclusive rights under the HPN-100 Technology; (ii) rights to commercialize the HPN-100 Technology,
(iii) exclusive rights under the Brusilow License Agreement, or (iv) rights to commercialize rights granted under the Brusilow License Agreement, and (b) there are no outstanding Liens made by Seller or its Affiliates on the HPN-100 Technology or the Brusilow License Agreement. 
 Section 5.09
Assigned Contracts. To Seller’s Knowledge, all Assigned Contracts are valid, binding and enforceable in accordance with their respective terms, subject to: (a) applicable bankruptcy, insolvency, reorganization, moratorium and
other Laws of general application affecting enforcement of creditors’ rights generally and by general equitable principles; and (b) Laws relating to the availability of specific performance, injunctive relief, or

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 23 of 45 

 
other equitable remedies against Seller and each other party thereto, and to the best of Seller’s Knowledge are in full force and effect. 

Section 5.10 No Breach. Since the effective date of the Prior Collaboration Agreement, Seller has not
received any written notice regarding any actual breach of, or default under any Assigned Contract (in particular, the Brusilow License Agreement). 

Section 5.11 Brusilow/Summar Agreements. Medicis has assigned to Seller all of its rights and interests
in and to the Brusilow License Agreement and the Summar Agreement. 
 Section 5.12 No Invalidity. To
Seller’s Knowledge, since the effective date of the Prior Collaboration Agreement, neither Seller nor any of its Affiliates has received any written notification from any Third Party alleging the invalidity or
non-enforceability of any Patents contained within the Product Rights. 

Section 5.13 No Infringement. To Seller’s Knowledge, since the effective date of the Prior
Collaboration Agreement, neither Seller nor any of its Affiliates has received any written notification from any Third Party alleging that the making, use or sale of Product infringes the Patents of such Third Party, and to Seller’s Knowledge,
without any duty to investigate, there is no basis for such an allegation with respect to UCD or HE. 

Section 5.14 Third Party Agreements. 

(a)    Section 5.14(a) of the Disclosure Schedules lists the only contracts with Third Parties to
which Seller or an Affiliate is a party that grant Seller licenses to intellectual property for the research, development or commercialization of the Product, except for licenses where the failure to transfer such licenses to Buyer hereunder would
not reasonably be expected to have or result in a Material Adverse Effect on Buyer’s rights with respect to the Product. 

(b)    Section 5.14(b) of the Disclosure Schedules lists the only contracts with Third Parties
to which Seller or an Affiliate is a party for the manufacture or distribution of the Product. 
 Section 5.15
Right to Grant Licenses. Seller has the right to grant to Buyer the licenses granted to Buyer under the Agreement as of the Signing Date. 

Section 5.16 All Necessary Rights. The rights and licenses granted to Buyer by Seller under the
Agreement constitute all of the rights and licenses in Seller’s possession as of the Signing Date that are necessary to exercise Buyer’s rights under the Agreement. 

ARTICLE VI 

REPRESENTATIONS AND WARRANTIES OF BUYER 

Buyer represents and warrants to Seller that the statements contained in this Article VI are true and correct as of the Signing Date.

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 24 of 45 

 Section 6.01 Organization of Buyer. Buyer is a
corporation duly organized, validly existing and in good standing under the Laws of the state of Delaware. 

Section 6.02 Authority of Buyer. Buyer has full corporate power and authority to enter into this
Agreement and the other Transaction Documents to which Buyer is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Buyer of this Agreement
and any other Transaction Document to which Buyer is a party, the performance by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the transactions contemplated hereby and thereby have been duly authorized by all
requisite corporate action on the part of Buyer. This Agreement has been duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by Seller) this Agreement constitutes a legal, valid and binding obligation of
Buyer enforceable against Buyer in accordance with its terms except as enforcement may be limited by general principles of equity (regardless of whether such enforceability is considered in a proceeding at law or in equity) and the effect of
applicable bankruptcy, insolvency, moratorium and other similar Laws of general application relating to or affecting creditors’ rights generally, including the effect of statutory or other Laws regarding fraudulent conveyances and preferential
transfers. When each other Transaction Document to which Buyer is or will be a party has been duly executed and delivered by Buyer (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will
constitute a legal and binding obligation of Buyer enforceable against it in accordance with its terms except as enforcement may be limited by general principles of equity (regardless of whether such enforceability is considered in a proceeding at
law or in equity) and the effect of applicable bankruptcy, insolvency, moratorium and other similar Laws of general application relating to or affecting creditors’ rights generally, including the effect of statutory or other Laws regarding
fraudulent conveyances and preferential transfers. 
 Section 6.03 No Conflicts; Consents. The
execution, delivery and performance by Buyer of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or
result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other organizational documents of Buyer; (b) conflict with or result in a violation or
breach of any provision of any Law or Governmental Order applicable to Buyer; or (c) require the consent, notice or other action by any Person under any contract to which Buyer is a party. No consent, approval, Permit, Governmental Order,
declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Buyer in connection with the execution and delivery of this Agreement and the other Transaction Documents and the consummation of the transactions
contemplated hereby and thereby. 
 Section 6.04 Brokers. No broker, finder or investment banker is
entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of Buyer. 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 25 of 45 

 Section 6.05 Sufficiency of Funds. Buyer has
sufficient cash on hand or other sources of funds available at the Closing to enable it to make payment of the Initial Purchase Price and consummate the transactions contemplated by this Agreement. 

Section 6.06 Legal Proceedings. There are no Actions pending or, to Buyer’s Knowledge, threatened
against or by Buyer or any Affiliate of Buyer that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise or serve as a basis for any
such Action. 
 ARTICLE VII 

COVENANTS 

Section 7.01 Confidentiality; Public Disclosure. 

(a)     From and after the Closing, Seller shall, and shall cause its Affiliates to, hold, and shall use commercially
reasonable efforts to cause its or their respective Representatives to hold, in confidence any and all information, whether written or oral, concerning the Assets, except to the extent that Seller can show that such information (i) is generally
available to and known by the public through no fault of Seller, any of its Affiliates or their respective Representatives; or (ii) is lawfully acquired by Seller, any of its Affiliates or their respective Representatives from and after the
Closing from sources which are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If Seller or any of its Affiliates or their respective Representatives are compelled to disclose any information by
judicial or administrative process or by other requirements of Law, Seller shall promptly notify Buyer in writing and shall disclose only that portion of such information which Seller is advised by counsel is legally required to be disclosed,
provided that Seller shall provide reasonable assistance if Buyer seeks to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information. 

(b)     Neither Party shall make any public announcement concerning the terms of this Agreement or the other Transaction
Documents without the prior written consent of the other Party, and such consent shall not be unreasonably withheld or delayed; provided, however, that a Party shall not be required to seek the consent of another Party to publicly disclose
any information regarding the terms of this Agreement or the other Transaction Documents to the extent that the disclosing Party can show that such information (i) is generally available to and known by the public through no fault of such
disclosing Party, any of its Affiliates or their respective Representatives; or (ii) is lawfully acquired by the disclosing Party, any of its Affiliates or their respective Representatives from and after the Closing from sources which are not
prohibited from disclosing such information by a legal, contractual or fiduciary obligation. Notwithstanding the foregoing, a Party may file a copy of this Agreement or the other Transaction Documents with a Governmental Authority or disclose the
terms thereof as required by Law; provided, however, that the non-disclosing Party is provided [***] (or such shorter period as may be required to permit timely filing or disclosure with the
Governmental Authority by the disclosing Party) notice prior to such disclosure or filing to review and comment on any filing or disclosure solely as it relates to the terms of the Agreement or the other Transaction Documents, including but not
limited to the right to request redaction of material financial and commercial 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 26 of 45 

 
terms to the extent permitted by applicable Law and the disclosing Party will consider in good faith any reasonable comments provided by the other Party during such period. Buyer acknowledges
that Medicis and its Affiliates are subject to a Corporate Integrity Agreement and that they shall have the right, without having to comply with the foregoing provisions, to disclose to the Office of the Inspector General (in the event Medicis deems
such disclosure is required to comply with the CIA) the fact that the transactions contemplated by this Agreement have occurred. To the extent that Medicis is required or requested to disclose the Agreement or the other Transaction Documents to the
Office of the Inspector General, Seller will comply with the provisions of this subsection (b). 
 (c)     Seller
and Buyer approve the content of the press release in the form of Schedule 7.01(c) for announcing the execution of this Agreement and the Amended and Restated Collaboration Agreement. Such press release may be released by one or both of Buyer
and Seller, and neither Party is required to participate in any joint press release. 
 (d)     Seller and Buyer agree
that the content of such press release, or any portion thereof, may be re-used by either Seller or Buyer as long as any such partial use of content is fair and accurate. 

(e)     Seller and Buyer each agree that Buyer shall have the right from and after the Closing to represent to Third
Parties that Buyer has acquired all rights to the Business without reservation by Seller. For the avoidance of doubt, after Closing, any press releases or other public announcements relating to the Product or the Business (except to the extent
disclosing the terms of this Agreement) shall be within the sole discretion of the Buyer. 
 Section 7.02 Non-competition. 
 (a)     For a period commencing on the Signing Date until the
later of (i) the expiration of the last patent covering the making, having made, selling, offering to sell, using and/or practicing of the Product in the United States or (ii) the expiration of any market exclusivity granted by the FDA for
the Product (the “Restricted Period”), Seller shall not, and shall not permit any of its Affiliates to, directly or indirectly, engage in or assist any other Person in engaging in the Restricted Business. 

(b)     If following the Restricted Period, the making, having made, selling, offering to sell, using and/or practicing of
Product is covered in a country or countries other than the United States by a Patent or other market exclusivity granted by a non-United States Governmental Authority comparable to the FDA, then the
Restricted Period shall continue in such country until the later of the last to expire patent covering the making, having made, selling, offering to sell, using and/or practicing of the Product in such country or expiration of any market exclusivity
in such country. 
 (c)     The restrictions set forth in this Section 7.02 shall not apply to
any and all of the following: 
 (i)     product as described in NDA 20-645, and
any supplements thereto, for the 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 27 of 45 

 
treatment of any indication approved by a Governmental Authority as of the Signing Date for so long as the Seller (including any successors and assigns other than Buyer) retains ownership of such
product; 
 (ii)     product as described in NDA 20-645, and any supplements
thereto, for [***] use in the treatment of [***] for so long as the Seller (including any successors and assigns other than Buyer) retains ownership of such product; 

(iii)     subject to subsection (v) and subsection (vi), product as described in NDA 20-572, and any supplements thereto, for use in any indication approved by a Governmental Authority as of the Signing Date for so long as the Seller (including any successors and assigns other than Buyer) retains
ownership of such product; and 
 (iv)     subject to subsection (v) and subsection (vi), product as
described in NDA 20-573, and any supplements thereto, for use in any indication approved by a Governmental Authority as of the Signing Date for so long as the Seller (including any successors and assigns other
than Buyer) retains ownership of such product. 
 (v)     Seller shall not, and shall not permit any of its Affiliates
to (directly or indirectly), [***] the products described in subsections (iii) and (iv) that: 

(A)    [***]; or 

(B)    [***]. 

(vi)     Seller shall not, and shall not permit any of its Affiliates to (directly or indirectly), [***] the products
described in subsections (iii) and (iv) that: 
 (A)    [***]; or 

(B)    [***]. 
 For the
avoidance of doubt, the foregoing limitations do not preclude Seller or its Affiliates from developing or commercializing products under separate regulatory approvals that are not otherwise prohibited by subsections (a) and (b),
including not precluding Seller or its Affiliates from developing or commercializing a [***] for the treatment of [***]. 

(d)     The terms of this Section 7.02 shall apply to Medicis and Seller’s other Affiliates
to the same extent as if they were parties hereto, and Seller and Medicis shall take whatever actions are within its control to cause any such other Persons to adhere to the terms of this Section 7.02. For clarity, this
Section 7.02 is binding on the successors and assigns of Seller, Medicis and their respective Affiliates. 

(e)     Seller acknowledges that a breach or threatened breach of this Section 7.02 may give
rise to irreparable harm to Buyer, for which monetary damages would not be an adequate remedy, and hereby agrees that in the event of a breach or a threatened breach by Seller of any such obligations, Buyer shall, in addition to any and all other
rights and remedies that may be 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 28 of 45 

 
available to it in respect of such breach, be entitled to seek equitable relief, including a temporary restraining order, an injunction, specific performance and any other relief that may be
available from a court of competent jurisdiction (without any requirement to post bond). 
 (f)     Seller acknowledges
that the restrictions contained in this Section 7.02 are reasonable and necessary to protect the legitimate interests of Buyer and constitute a material inducement to Buyer to enter into this Agreement and consummate the
transactions contemplated by this Agreement. In the event that any covenant contained in this Section 7.02 should ever be adjudicated to exceed the time, geographic, product or service or other limitations permitted by
applicable Law in any jurisdiction, then any court is expressly empowered to reform such covenant, and such covenant shall be deemed reformed, in such jurisdiction to the maximum time, geographic, product or service or other limitations permitted by
applicable Law. The covenants contained in this Section 7.02 and each provision hereof are severable and distinct covenants and provisions. The invalidity or unenforceability of any such covenant or provision as written
shall not invalidate or render unenforceable the remaining covenants or provisions hereof, and any such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such covenant or provision in any other
jurisdiction. 
 (g)     Each of Seller and Buyer and their respective Affiliates shall be permitted to use the same
suppliers of finished products, components and raw materials, including active pharmaceutical ingredient, and none of Seller, Buyer and their respective Affiliates will enter into an agreement with a Third Party that precludes the other Party or its
Affiliates from use of such suppliers. 
 Section 7.03 Transfer of Product Registrations. Seller and Buyer
each agree to use commercially reasonable efforts to effect, as soon as reasonably practicable following Closing, the transfer from Seller to Buyer, of all Seller’s rights, title and interest to the Product Registrations included in the Product
Rights; and to the extent that transfer of such Product Registrations is delayed, Seller shall reasonably co-operate with Buyer and use commercially reasonable efforts to place Buyer in the functionally
equivalent position as if such assets had been so transferred or assigned during such delay. 
 (a)     Seller and Buyer
each agree to prepare and file whatever filings, requests or applications are required or deemed advisable to be filed with any Governmental Authorities in connection with the transactions contemplated by this Agreement, including the FDA Transfer
of Ownership Letters with respect to the transfer of the NDA for Product from Seller to Buyer and equivalent letters for transfer of the IND for Product from Seller to Buyer, and to cooperate with one another as reasonably necessary to accomplish
the foregoing. 
 (b)     Seller and Buyer shall: (i) diligently take, or fully cooperate in the taking of, all
necessary and proper steps to make such filings as required or deemed advisable pursuant to this Section 7.03(b), (ii) take, or cause to be taken, all actions, and to do or cause to be done, and to assist and cooperate
with the other Party in doing all things reasonably necessary, proper, and/or advisable under applicable Law or otherwise (A) to consummate and make effective the transactions contemplated by this Agreement and (B) obtain from any
Governmental Authority any non-actions, clearances, waivers, consents, approvals, authorizations, permits or orders 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 29 of 45 

 
required to be obtained in connection with the execution and performance of this Agreement or the transactions contemplated by this Agreement. 

(c)     Except as otherwise provided in this Agreement, from and after Closing, Buyer shall assume all regulatory
responsibilities in connection with the Product and the Product Registrations, including responsibility for (i) all periodic and annual reports or other regulatory filings with the FDA with respect to the 2012 calendar year (provided that
Seller shall provide assistance as reasonably requested in connection with such reports and filings), (ii) reporting any adverse drug events in connection with the NDA for Product, and (iii) compliance with the Federal Food, Drug and
Cosmetic Act and the Public Health Service Act, as the same may be amended from time to time. 
 (d)     From and after
Closing, Buyer shall have all responsibility for any and all Governmental Authority fee obligations for holders or owners of the Product Registrations that relate to periods prior to, on and after the Signing Date. 

(e)     From and after Closing, Buyer shall have the sole authority and responsibility to respond to, correspond with,
and/or make any filings with any Governmental Authorities, to respond to product technical complaints and medical complaints and to handle all recalls, market withdrawals and field corrections of the Product in accordance with applicable Laws, all
at Buyer’s sole cost and expense. 
 Section 7.04 Governmental Approvals and Consents. 

(a)     Each Party hereto shall, as promptly as possible, (i) make, or cause or be made, all filings and submissions
required under any Law applicable to such Party or any of its Affiliates; and (ii) use commercially reasonable efforts to obtain, or cause to be obtained, all consents, authorizations, orders and approvals from all Governmental Authorities that
may be or become necessary for its execution and delivery of this Agreement and the performance of its obligations pursuant to this Agreement and the other Transaction Documents. Each Party shall cooperate fully with the other Party and its
Affiliates in promptly seeking to obtain all such consents, authorizations, orders and approvals. The Parties hereto shall not willfully take any action that will have the effect of delaying, impairing or impeding the receipt of any required
consents, authorizations, orders and approvals. 
 (b)     Seller and Buyer shall use commercially reasonable efforts to
give all notices to, and obtain all consents from, all Third Parties that are described in Section 5.03 and Section 6.03 of the Disclosure Schedules. 

(c)     Without limiting the generality of the Parties’ undertakings pursuant to subsections (a) and
(b) above, each of the Parties hereto shall use commercially reasonable efforts to: 
 (i)     respond to
any inquiries by any Governmental Authority regarding antitrust or other matters with respect to the transactions contemplated by this Agreement or any other Transaction Document; 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 30 of 45 

 (ii)     avoid the imposition of any order or the taking of any action
that would restrain, alter or enjoin the transactions contemplated by this Agreement or any other Transaction Document; and 

(iii)     in the event any Governmental Order adversely affecting the ability of the Parties to consummate the
transactions contemplated by this Agreement or any other Transaction Document has been issued, to have such Governmental Order vacated or lifted. 

(d)     Except as otherwise set forth in this Agreement, all meetings, discussions, appearances, analyses, presentations,
memoranda, briefs, filings, arguments, and proposals made by or on behalf of either Party before any Governmental Authority or the staff or regulators of any Governmental Authority, in connection with the transactions contemplated hereunder (but,
for the avoidance of doubt, not including any interactions between Seller or Buyer with Governmental Authorities in the ordinary course of business, any disclosure which is not permitted by Law or any disclosure containing confidential information)
shall be disclosed to the other Party hereunder in advance of any filing, submission or attendance, it being the intent that the Parties will consult and cooperate with one another, and consider in good faith the views of one another, in connection
with any such meetings, discussions, appearances, analyses, presentations, memoranda, briefs, filings, arguments, and proposals. Except as otherwise set forth in this Agreement, each Party shall give notice to the other Party with respect to any
such meeting, discussion, or appearance with any Governmental Authority or the staff or regulators of any Governmental Authority, with such notice being sufficient to provide the other Party with the opportunity to attend and participate in such
meeting, discussion, or appearance. 
 (e)     Notwithstanding the foregoing, nothing in this
Section 7.04 shall require, or be construed to require, Buyer or any of its Affiliates to agree to (i) sell, hold, divest, discontinue or limit, before or, subject to Section 10.07, after the
Signing Date, any assets, businesses or interests of Buyer or any of its Affiliates; (ii) any conditions relating to, or changes or restrictions in, the operations of any such assets, businesses or interests which, in either case, could
reasonably be expected to result in a Material Adverse Effect or materially and adversely impact the economic or business benefits to Buyer of the transactions contemplated by this Agreement and the other Transaction Documents; or (iii) any
material modification or waiver of the terms and conditions of this Agreement. 
 Section 7.05 Patent
Prosecution and Maintenance. 
 (a)     Seller’s Rights. Subject to this
Section 7.05, as between Buyer and Seller, Seller shall have the first right to file, prosecute, and maintain Ucyclyd Manufacturing Patents. If Seller files a Ucyclyd Manufacturing Patent under this
Section 7.05(a), following the date of such filing, Seller shall provide Buyer with a copy of the filed application, office action, response to office action, request for terminal disclaimer, request for reissue or
reexamination with respect to such Ucyclyd Manufacturing Patent and Buyer shall have the right to provide any comments or suggestions with respect to such filing and the continued prosecution and amendment of such filing, including any reasonably
requested claim amendments to any patent application, responses to office actions or requests for reissue or reexamination. Seller shall use good faith efforts to consider such comments and suggestions. The Parties agree that the Parties have a

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 31 of 45 

 
common interest with respect to the Ucyclyd Manufacturing Patents. For clarity, as of the Signing Date, [***]. 

(b)     Buyer’s Rights Post-Closing. Effective upon the Closing, Buyer shall have the sole right to
control prosecution and maintenance of the HPN-100 Patents. Following the Signing Date, Seller shall transfer to Buyer any and all documents constituting or comprising Seller’s patent prosecution files
for the HPN-100 Patents in accordance with Section 7.08. Seller shall assist and cooperate with Buyer, upon Buyer’s request and Buyer’s sole expense, in Buyer’s filing,
prosecution or maintenance of the HPN-100 Patents. For the avoidance of doubt, following the Closing, Seller shall maintain the rights with respect to control of prosecution and maintenance of the Ucyclyd
Manufacturing Patents as set forth in Section 7.05(a). The Parties agree that the Parties have a common interest with respect to the Ucyclyd Manufacturing Patents. 

(c)     Patent Prosecution and Maintenance Costs. On and after the Closing, (A) Buyer shall be responsible
solely for any and all Third Party costs and expenses incurred in connection with any filings, prosecution and maintenance of any HPN-100 Patents, and (B) Seller shall be responsible for any and all Third
Party costs and expenses incurred in connection with any filings, prosecution and maintenance of any Ucyclyd Manufacturing Patents. 

Section 7.06 Bulk Sales Laws. The Parties hereby waive compliance with the provisions of any bulk sales, bulk
transfer or similar Laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Product Rights to Buyer; it being understood that any Liabilities arising out of the failure of Seller to comply with the
requirements and provisions of any bulk sales, bulk transfer or similar Laws of any jurisdiction which would not otherwise constitute Assumed Liabilities shall be treated as Excluded Liabilities. 

Section 7.07 Transfer Taxes. All transfer, documentary, sales, use, stamp, registration,
value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the other Transaction Documents (including any real property transfer Tax and any other similar Tax) shall be borne and
paid by [***] when due. Seller shall, at its own expense, timely file any Tax Return or other document with respect to such Taxes or fees (and Buyer shall cooperate with respect thereto as necessary). 

Section 7.08 Technology Transfer and Product Records. No later than [***] after the Signing Date, Seller
shall deliver to Buyer (a) all copies of Product Records (regardless of whether such Product Records are already in Buyer’s possession), subject to the retention rights specified in the definition of Product Records and (b) any HPN-100 Know-How not already in Buyer’s possession at the time of Closing. 

Section 7.09 Perfection of IP Rights. On and following Closing, Seller shall, on behalf of itself and
all Affiliates, cooperate with Buyer to provide all assistance to and execute all documents reasonably required by Buyer to establish, assign, perfect and affirm any and all of Buyer’s rights in the
HPN-100 Technology; provided that, in the case of any cooperation provided by Seller following [***], Buyer agrees to reimburse Seller for the actual, documented, out-of-pocket costs and expenses incurred by Seller in connection with such cooperation. Seller 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 32 of 45 

 
shall use commercially reasonable efforts to secure the signature of Seller or its Affiliates (as the case may be) to any document required to file, prosecute, register or memorialize the
assignment of any rights as set forth in this Section 7.09; provided, however, if Buyer is unable to secure such signature within [***] of any request by Buyer for such signature, Seller hereby irrevocably designates
and appoints Buyer and Buyer’s duly authorized officers and agents as Seller’s agents and attorneys-in-fact to act for and on Seller’s behalf and instead
of Seller solely to the extent required to further the filing, prosecution, registration, memorializing of assignment, issuance and enforcement of such rights and only to the extent Seller was unable to secure such signature, all with the same legal
force and effect as if executed by Seller. The foregoing is deemed a power coupled with an interest and is irrevocable. 

Section 7.10 Further Assurances. Following the Closing, each of the Parties hereto shall, and shall
cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the
transactions contemplated by this Agreement and the other Transaction Documents. 
 Section 7.11 Adverse Events
and Safety Reporting. The Parties have previously entered into that certain Safety Data Exchange Agreement, dated August 23, 2007 (“SDEA”), which governs disclosure between the Parties of safety-related information
relevant to Buphenyl and Product. The Parties agree that, effective as of the Signing Date, the SDEA hereby is terminated. 
 ARTICLE VIII

 INDEMNIFICATION 

Section 8.01 Survival. Subject to the limitations and other provisions of this Agreement, the
representations and warranties contained herein shall survive the Closing and shall remain in full force and effect until the date that is [***] after the Signing Date; provided, that the representations and warranties in
Section 5.01, Section 5.02, Section 5.04, Section 5.07, Section 6.01, Section 6.02 and
Section 6.04 shall survive [***]. All covenants and agreements of the Parties contained herein shall survive the Closing indefinitely or for the period explicitly specified therein. Notwithstanding the foregoing, any claims
asserted in good faith with reasonable specificity (to the extent known at such time) and in writing by notice from the non-breaching Party to the breaching Party prior to the expiration date of the applicable
survival period shall not thereafter be barred by the expiration of the relevant representation or warranty and such claims shall survive until finally resolved. 

Section 8.02 Indemnification By Seller. Subject to the other terms and conditions of this Agreement
(including Article VIII), Seller shall indemnify and defend each of Buyer and its Affiliates and their respective Representatives (collectively, the “Buyer Indemnitees”) against, and shall hold each of them harmless from and
against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Buyer Indemnitees based upon, arising out of, with respect to or by reason of: 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 33 of 45 

 (a)     any inaccuracy in or breach of any of the representations or
warranties of Seller contained in this Agreement, the other Transaction Documents or in any certificate or instrument delivered by or on behalf of Seller pursuant to this Agreement; 

(b)     any breach or non-fulfillment of any covenant, agreement or obligation to
be performed by Seller pursuant to this Agreement, the other Transaction Documents or any certificate or instrument delivered by or on behalf of Seller pursuant to this Agreement; or 

(c)     any Excluded Asset or any Excluded Liability. 

Section 8.03 Indemnification By Medicis. Subject to the other terms and conditions of this Agreement
(including Article VIII), Medicis shall indemnify and defend the Buyer Indemnitees against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or
imposed upon, the Buyer Indemnitees based upon, arising out of, with respect to or by reason of: 
 (a)     any
inaccuracy in or breach of any of the representations or warranties of Medicis contained in this Agreement; or 

(b)     any breach or non-fulfillment of any covenant, agreement or obligation to
be performed by Medicis pursuant to this Agreement. 
 Section 8.04 Indemnification By Buyer. Subject to
the other terms and conditions of this Agreement (including Article VIII), Buyer shall indemnify and defend each of Seller and its Affiliates and their respective Representatives (collectively, the “Seller Indemnitees”)
against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Seller Indemnitees based upon, arising out of, with respect to or by
reason of: 
 (a)     any inaccuracy in or breach of any of the representations or warranties of Buyer contained in this
Agreement or in any certificate or instrument delivered by or on behalf of Buyer pursuant to this Agreement; 
 (b)    
any breach or non-fulfillment of any covenant, agreement or obligation of Buyer pursuant to this Agreement or under any Assigned Contract; 

(c)     any claim by the Brusilow Licensors for indemnification that is based on the acts or omissions of any of the Buyer
Indemnitees, whether arising before, on or after the Signing Date; 
 (d)     any actual or alleged breach or failure to
perform of the obligations to be performed by Hyperion in connection with the Brusilow License Agreement, whether arising before, on or after the Signing Date; or 

(e)     any Assumed Liability. 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 34 of 45 

 Section 8.05 Certain Limitations. The indemnification
provided for in Section 8.02 and Section 8.03 shall be subject to the following limitations: 

(a)     Seller shall not be liable to the Buyer Indemnitees for indemnification under
Section 8.02(a) (other than with respect to a claim for indemnification based upon, arising out of, with respect to or by reason of any inaccuracy in or breach of any representation or warranty in [***] (the “Buyer
Section 8.05(a) Basket Exclusions”)), until the aggregate amount of all Losses in respect of indemnification under Section 8.02(a) (other than those based upon, arising out of, with respect to or
by reason of the Buyer Section 8.05(a) Basket Exclusions) exceeds $[***], in which event Seller shall be required to pay or be liable for all such Losses from the first dollar. 

(b)     Buyer shall not be liable to the Seller Indemnitees for indemnification under
Section 8.04(a) (other than with respect to a claim for indemnification based upon, arising out of, with respect to or by reason of any inaccuracy in or breach of any representation or warranty in [***] (the “Seller
Basket Exclusions”)) until the aggregate amount of all Losses in respect of indemnification under Section 8.04(a) (other than those based upon, arising out of, with respect to or by reason of the Seller Basket
Exclusions) exceeds $[***], in which event Buyer shall be required to pay or be liable for all such Losses from the first dollar. 

(c)     Medicis shall not be liable to the Buyer Indemnitees for indemnification under
Section 8.03(a) (other than with respect to a claim for indemnification based upon, arising out of, with respect to or by reason of any inaccuracy in or breach of any representation or warranty in [***] (the “Buyer
Section 8.05(c) Basket Exclusions”)), until the aggregate amount of all Losses in respect of indemnification under Section 8.03(a) (other than those based upon, arising out of, with respect to or
by reason of the Buyer Section 8.05(c) Basket Exclusions) exceeds $[***], in which event Medicis shall be required to pay or be liable for all such Losses from the first dollar. 

(d)     Seller shall have no liability (for indemnification or otherwise) with respect to claims under
Section 8.02(a) for Losses that, in the aggregate, exceed an amount equal to [***]; provided, however, this Section 8.05(d) will not apply to claims against Seller arising in respect of
[***]. 
 (e)     Medicis shall have no liability (for indemnification or otherwise) with respect to claims under
Section 8.03(a) for Losses that, in the aggregate, exceed an amount equal to [***]; provided, however, this Section 8.05(e) will not apply to claims against Medicis arising in respect of
[***]. 
 (f)     Buyer shall have no liability (for indemnification or otherwise) with respect to claims under
Section 8.04(a) for Losses that, in the aggregate, exceed an amount equal to [***]; provided, however, this Section 8.05(f) will not apply to claims arising in respect of [***]. 

Section 8.06 Indemnification Procedures. The Party making a claim under this Article VIII is
referred to as the “Indemnified Party”, and the Party against whom such claims are asserted under this Article VIII is referred to as the “Indemnifying Party”. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 35 of 45 

 (a)     Third Party Claims. If any Indemnified Party
receives notice of the assertion or commencement of any Action made or brought by any Person who is not a party to this Agreement or an Affiliate of a Party to this Agreement or a Representative of the foregoing (a “Third Party
Claim”) against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party reasonably prompt written notice
thereof, but in any event not later than [***] after receipt of such notice of such Third Party Claim; provided, however, the failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification
obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Third Party Claim in reasonable detail, shall include copies of all
material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have the right to participate in, or by giving
written notice to the Indemnified Party, to assume the defense of any Third Party Claim at the Indemnifying Party’s expense and by the Indemnifying Party’s own counsel, and the Indemnified Party shall cooperate in good faith in such
defense. In the event that the Indemnifying Party assumes the defense of any Third Party Claim, subject to Section 8.06(b), it shall have the right to take such action as it deems necessary to avoid, dispute, defend, appeal
or make counterclaims pertaining to any such Third Party Claim in the name and on behalf of the Indemnified Party. The Indemnified Party shall have the right to participate in the defense of any Third Party Claim at the Indemnified Party’s own
cost with counsel selected by it subject to the Indemnifying Party’s right to control the defense thereof. The fees and disbursements of such counsel shall be at the expense of the Indemnified Party, provided, that if in the reasonable
opinion of counsel to the Indemnified Party, there exists a conflict of interest between the Indemnifying Party and the Indemnified Party that cannot be waived, the Indemnifying Party shall be liable for the reasonable fees and expenses of counsel
to the Indemnified Party in each jurisdiction for which counsel to the Indemnified Party determines that different counsel is required. If the Indemnifying Party elects not to defend such Third Party Claim, fails to promptly notify the Indemnified
Party in writing of its election to defend as provided in this Agreement, or fails to prosecute the defense of such Third Party Claim, the Indemnified Party may, subject to Section 8.06(b), pay, compromise, defend such
Third Party Claim and seek indemnification for any and all Losses based upon, arising from or relating to such Third Party Claim; provided, however, the Indemnifying Party shall have the right to defend such Third Party Claim at any time
following the assumption of the defense by the Indemnified Party. Seller and Buyer shall cooperate with each other in all reasonable respects in connection with the defense of any Third Party Claim, including making available (subject to the
provisions of Section 7.04) records relating to such Third Party Claim and furnishing, without expense (other than reimbursement of actual
out-of-pocket expenses) to the defending Party, management employees of the non-defending Party as may be reasonably necessary
for the preparation of the defense of such Third Party Claim. 
 (b)     Settlement of Third Party
Claims. Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not enter into settlement of any Third Party Claim without the prior written consent of the Indemnified Party, except as provided in this
Section 8.06(b). If a firm offer is made to settle a Third Party Claim without leading to liability or the 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 36 of 45 

 
creation of a financial or other obligation on the part of the Indemnified Party and provides, in customary form, for the unconditional release of each Indemnified Party from all liabilities and
obligations in connection with such Third Party Claim and the Indemnifying Party desires to accept and agree to such offer, the Indemnifying Party shall give written notice to that effect to the Indemnified Party. If the Indemnified Party fails to
consent to such firm offer within [***] after its receipt of such notice, the Indemnified Party may continue to contest or defend such Third Party Claim and in such event, the maximum liability of the Indemnifying Party as to such Third Party Claim
shall not exceed the amount of such settlement offer. If the Indemnified Party fails to consent to such firm offer and also fails to assume defense of such Third Party Claim, the Indemnifying Party may settle the Third Party Claim upon the terms set
forth in such firm offer to settle such Third Party Claim. If the Indemnified Party has assumed the defense pursuant to Section 8.06(a), it shall not agree to any settlement without the written consent of the Indemnifying
Party (which consent shall not be unreasonably withheld or delayed). 
 (c)     Direct Claims. Any Action by
an Indemnified Party on account of a Loss which does not result from a Third Party Claim (a “Direct Claim”) shall be asserted by the Indemnified Party giving the Indemnifying Party reasonably prompt written notice thereof, but in
any event not later than [***] after the Indemnified Party becomes aware of such Direct Claim provided, however, the failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification
obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all
material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have [***] after its receipt of such notice to
respond in writing to such Direct Claim. The Indemnified Party shall allow the Indemnifying Party and its professional advisors to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any
amount is payable in respect of the Direct Claim and the Indemnified Party shall assist the Indemnifying Party’s investigation by giving such information and assistance (including access to the Indemnified Party’s premises and personnel
and the right to examine and copy any accounts, documents or records) as the Indemnifying Party or any of its professional advisors may reasonably request. If the Indemnifying Party does not so respond within such [***] period, the Indemnifying
Party shall be deemed to have rejected such claim, in which case the Indemnified Party shall be free to pursue such remedies as may be available to the Indemnified Party on the terms and subject to the provisions of this Agreement. 

Section 8.07 Payments. Once a Loss is agreed to by the Indemnifying Party or finally adjudicated to be
payable pursuant to this Article VIII, the Indemnifying Party shall satisfy its obligations within [***] of such final, non-appealable adjudication by wire transfer of immediately available funds. The
Parties hereto agree that should an Indemnifying Party not make full payment of any such obligations within such [***] period, any amount payable shall accrue interest from and including the date of agreement of the Indemnifying Party or final, non-appealable adjudication to and including the date such payment has been made at the rate per annum announced by Bank of America (or its successor) as its prime rate in effect on first day of

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 37 of 45 

 
such period plus [***] percent ([***]%). Such interest shall be calculated daily on the basis of a 365 day year and the actual number of days elapsed, without compounding. 

Section 8.08 Tax Treatment of Indemnification Payments. All indemnification payments made under this
Agreement by Seller or Buyer shall be treated by the Parties as an adjustment to the Purchase Price for Tax purposes, unless otherwise required by Law. 

Section 8.09 Effect of Investigation. Buyer acknowledges that after the Signing Date of the Prior
Collaboration Agreement, Buyer has been the Party primarily conducting the Business, and it has had the opportunity to conduct due diligence and investigation with respect to the Business, Product Rights and other Assets. In no event shall Seller or
Medicis have any liability to the Buyer, or any obligation to provide indemnification therefor, with respect to a breach of representation, warranty, covenant or obligation under this Agreement to the extent (a) the inaccuracy of the applicable
representation, warranty, covenant or obligation was, as of the Signing Date, within the Knowledge of Buyer or (b) directly caused by from Buyer’s conduct of the Business prior to, on or after the Signing Date. 

Section 8.10 Exclusive Remedies. Subject to Section 7.05,
Section 10.11 and Article IX, the Parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims (other than claims arising from fraud, criminal activity or willful misconduct
on the part of a Party hereto in connection with the transactions contemplated by this Agreement) for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this
Agreement, shall be pursuant to the indemnification provisions set forth in this Article VIII. In furtherance of the foregoing, each Party hereby waives, to the fullest extent permitted under Law, any and all rights, claims and causes of
action for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement it may have against the other Parties hereto and their Affiliates and each of
their respective Representatives arising under or based upon any Law, except pursuant to the indemnification provisions set forth in this Article VIII; provided, however, nothing in this Section 8.10 shall
limit: (a) the rights of the Parties under Article IX; (b) any Person’s right to seek and obtain any equitable relief to which any Person shall be entitled; or (c) any Person’s right to seek and obtain any remedy on
account of any Person’s fraudulent, criminal or intentional misconduct. 
 ARTICLE IX 

TERMINATION 

Section 9.01 Termination of Licenses. Seller on the one hand and Buyer on the other shall have the right, but
not the obligation, to terminate a royalty-bearing or fee-bearing license granted to the other Party under Article IV of the Agreement, in the event the breaching Party fails to pay to the non-breaching Party under the Agreement an amount due with respect to such license and such non-payment is not remedied within [***] following the receipt of written notice of
such non-payment from the non-breaching Party. Such termination shall be effective on the expiration of such notice period if the breaching Party has failed to remedy
such non-payment prior to the expiration of such notice period. Termination of a license under Article IV shall not affect any other licenses under Article IV. With respect to any non-payment of the royalty for 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 38 of 45 

 
products for New Indications in Section 4.02(d), Buyer shall have the right to terminate all rights granted to Seller with respect to [***] (but not with respect to
[***]). In the event payment under this Agreement is disputed in good faith, the license shall not be terminated pending resolution of the dispute under Section 10.10, if the dispute is resolved such that payment is due,
the license shall not be terminated unless and until the breaching Party fails to make such payment within [***] after final resolution. 

ARTICLE X 

MISCELLANEOUS 

Section 10.01 Expenses. Except as otherwise expressly provided herein, all costs and expenses, including
fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party incurring such costs and expenses, whether or not the Closing shall
have occurred. 
 Section 10.02 Notices. Except as otherwise set forth in the Agreement, in any case where
any notice or other communication is required or permitted to be given under the Agreement, such notice or communication shall be in writing, and sent by overnight express or registered or certified mail (with return receipt requested) or sent via
facsimile with confirmation by overnight express or registered or certified mail (with return receipt requested) with the recipient and shall be sent to the following address (or such other address as either Party may designate from time to time in
writing): 
 If to Hyperion: 
 Hyperion
Therapeutics, Inc. 
 601 Gateway Boulevard, Suite 200 

South San Francisco, California 94080 

Telephone: (650) 745-7802 

Fax: (650) 745-3568 

Attention: Chief Executive Officer 
 With a copy
to: 
 Hogan Lovells LLP 
 525
University Ave., 3rd Floor 
 Palo Alto, CA 94301 

Attention: Laura Berezin 

Telephone: (650) 463 4000 

Fax: (650) 463-4199 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 39 of 45 

 If to Ucyclyd: 

Ucyclyd Pharma, Inc. 
 7720 North
Dobson Road 
 Scottsdale, AZ 85256 

Attention: President 
 Facsimile: (480) 291-5163 
 With copies to: 

Ucyclyd Pharma, Inc. 
 7720 North
Dobson Road 
 Scottsdale, AZ 85256 

Attention: Legal Department 

Facsimile: (480) 291-5163 

If to Medicis: 
 Medicis Pharmaceutical
Corporation 
 7720 North Dobson Road 

Scottsdale, AZ 85256 
 Attention:
Chief Executive Officer 
 Facsimile: (480) 291-5163 

With copies to: 
 Medicis Pharmaceutical
Corporation 
 7720 North Dobson Road 

Scottsdale, AZ 85256 
 Attention:
Legal Department 
 Facsimile: (480) 291-5163 

Section 10.03 Interpretation. For purposes of this Agreement, (a) the words “include,”
“includes” and “including” shall be deemed to be followed by the words “without limitation”; (b) the word “or” is not exclusive; and (c) the words “herein,” “hereof,”
“hereby,” “hereto” and “hereunder” refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Disclosure Schedules and Exhibits mean the Articles and
Sections of, and Disclosure Schedules and Exhibits attached to, this Agreement; (y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the
extent permitted by the provisions thereof and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall be construed without
regard to any presumption or rule requiring construction or interpretation against the Party drafting an instrument or causing any instrument to be drafted. 

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 40 of 45 

 The Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part
of, this Agreement to the same extent as if they were set forth verbatim herein. 
 Section 10.04
Headings. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement. 

Section 10.05 Severability. If any term or provision of this Agreement is invalid, illegal or
unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Except as
provided in Section 7.02(f), upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the
original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible. 

Section 10.06 Entire Agreement. This Agreement and the other Transaction Documents constitute the sole
and entire agreement of the Parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject
matter, including the [***]. In the event of any inconsistency between the statements in the body of this Agreement and those in the other Transaction Documents, the Exhibits and Disclosure Schedules (other than an exception expressly set forth as
such in the Disclosure Schedules), the statements in the body of this Agreement will control. 
 Section 10.07
Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and permitted assigns. No Party may assign its rights or obligations hereunder without the
prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that following the Signing Date, a Party may, without the prior written consent of the other Party, assign all or any
portion of its rights under this Agreement to (a) to an Affiliate or (b) to any Person pursuant to a Change in Control (including without limitation an acquirer or other transferee of all or substantially all of such Party’s business
relating to this Agreement, whether by merger, acquisition, sale of stock, sale or assets, or otherwise). No assignment shall relieve the assigning Party of any of its obligations hereunder. 

Section 10.08 No Third-party Beneficiaries. Except as provided in Article VIII, this Agreement is
for the sole benefit of the Parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy
of any nature whatsoever under or by reason of this Agreement. 
 Section 10.09 Amendment and Modification;
Waiver. 
 (a)    This Agreement may only be amended, modified or supplemented by an agreement in writing signed by
each Party hereto. For clarity, the Parties agree that any agreement contained in an electronic mail communication shall not constitute a “written 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 41 of 45 

 
agreement” and the Agreement will be varied, amended or extended only pursuant to a written separate document that is signed with “wet” signatures by duly authorized officers or
representatives, specifically referring to the Agreement. 
 (b)     No waiver by any Party of any of the provisions
hereof shall be effective unless explicitly set forth in writing and signed by the Party so waiving. No waiver by any Party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such
written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be
construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. 

Section 10.10 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial. 

(a)     Governing Law. 

(i)     Except as set forth in subsection (a)(ii) below, the Agreement shall be governed by the laws of the State
of Delaware (other than with respect to principles of conflicts of laws thereunder). 
 (ii)    All matters relating to
this Section 10.10 and any arbitration hereunder shall be governed by the Federal Arbitration Act, Chapters 1 and 2. 

(b)     Dispute Resolution Procedure. 

(i)    Except for any disputes with respect to the coverage, validity or enforceability of any Patent (which shall be
resolved in federal courts with competent jurisdiction), all other disputes shall be finally settled by arbitration administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules (the
“Rules”). 
 (ii)    The dispute shall be resolved by a panel of three (3) arbitrators (the
“Arbitration Panel”). As long as they are each able and available to perform the duties of an arbitrator, the Arbitration Panel shall consist of the following three arbitrators: [***], [***] and [***]. If only one of these
arbitrators gives notice that he or she is unable or unavailable to serve on the Arbitration Panel, then the remaining two arbitrators shall select a replacement for that arbitrator within [***] of such notice. Under such circumstances, no ex
parte communications between the remaining arbitrators and the Parties regarding selection of a replacement arbitrator shall be allowed. If more than one of these arbitrators is unable or unavailable to serve on the Arbitration Panel regarding
the dispute, then the entire Arbitration Panel shall be reconstituted as follows: within [***] after the commencement of arbitration, each Party shall select one Person to act as arbitrator, and the two (2) so selected shall select a third
arbitrator within [***] of the commencement of the arbitration. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator within the allotted time, the third arbitrator shall be appointed by

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 42 of 45 

 
the American Arbitration Association in accordance with the Rules. All arbitrators shall serve as neutral, independent and impartial arbitrators. Each arbitrator shall have at least [***]
experience with pharmaceutical, commercial or intellectual property matters as the nature of the dispute may require. 
 (iii)
    The arbitration shall take place in Los Angeles, California. 
 (iv)     Except as may be
required by applicable Law, no Party to this Agreement nor its representatives nor a witness nor an arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of the other Parties. Any
documentary or other evidence given by a Party or witness in the arbitration shall be treated as confidential by any Party whose access to such evidence arises exclusively as a result of its participation in the arbitration, and shall not be
disclosed to any Third Party (other than a witness or expert), except as may be required by applicable Law. 
 (v)
    Discovery will be limited to the request for and production of documents and depositions. For clarity, there shall be no interrogatories or requests to admit. With regard to electronic discovery, (A) there shall be
production of electronic documents only from sources used in the ordinary course of business; (B) absent a showing of compelling need, no such documents are required to be produced from backup servers, tapes or other media; (C) the
description of custodians from whom electronic documents may be collected shall be narrowly tailored to include only those individuals whose electronic documents may reasonably be expected to contain evidence that is material to the dispute, and
(D) where the costs and burdens of e-discovery are disproportionate to the nature of the dispute or to the amount in controversy, or to the relevance of the materials requested, the Arbitration Panel will
either deny such requests or order disclosure on condition that the requesting Party advance the reasonable cost of production to the other side, subject to the allocation of costs in the final award. Subject to the foregoing limitations, all
discovery will be guided by the Federal Rules of Civil Procedure. All issues concerning discovery upon which the Parties cannot agree will be submitted to the Arbitration Panel for determination. 

(vi)     The arbitrators shall have the right to award or include in their award any relief which they deem proper in the
circumstances, including money damages (with interest on unpaid amounts from date due), specific performance, injunctive relief, reasonable legal fees, costs and expenses in accordance with subsection (vii) below; provided,
however, that the Arbitration Panel’s award shall in no event include the award of any consequential, punitive, exemplary or treble damages as to which the Parties hereby expressly and irrevocably waive any right, except for damages
resulting from a breach of a Party’s confidentiality obligations under this Agreement and except for consequential damages that fall within the definition of a Loss. For the avoidance of doubt, any damages awarded to a Third Party for which a
Party is obligated to indemnify the other Party in accordance with Article VIII of this Agreement shall be considered direct damages and, therefore, is not subject to any cap on liability. 

(vii)     The Arbitration Panel shall award to the prevailing Party, if any, as determined by the Arbitration Panel, an
amount equal to [***] percent ([***]%) of its costs and expenses (including reasonable attorneys’ fees) incurred in connection with the arbitration. If the 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 43 of 45 

 
Arbitration Panel determines a Party to be the prevailing Party under circumstances where the prevailing Party won on some but not all of the claims and counterclaims, the arbitrator(s) may award
the prevailing Party a percentage below [***] percent ([***]%) of the reasonable costs and expenses (including attorneys’ fees) incurred by the prevailing Party in connection with the arbitration, as appropriate to reflect the level of winning
claims and counterclaims. 
 (viii)     Notwithstanding the foregoing, a Party has the right to apply to any court of
competent jurisdiction for provisional relief, including pre-arbitral attachments, a temporary restraining order, temporary injunction, permanent injunction or order of specific performance, as may appear
reasonably necessary to preserve the rights of a Party. The application by either Party to a judicial authority for such measures shall not be deemed to be an infringement or a waiver of the arbitration agreement and shall not affect the relevant
powers reserved to the arbitrator. If a Party institutes any action or proceeding to preserve its rights pursuant to this subsection (viii) then the prevailing Party in such action or proceeding shall reimburse the other Party for its
reasonable costs and expenses incurred including attorneys’ fees. 
 (ix)     Judgment upon any award(s) rendered
by the arbitrator(s) may be entered in any court having jurisdiction thereof. The Parties hereby waive all objection which it may have at any time to the laying of venue of any proceedings brought in such courts, waives any claim that such
proceedings have been brought in an inconvenient forum and further waives the right to object with respect to such proceedings that any such court does not have jurisdiction over such Party. 

(c)     Waiver of Jury Trial. Each Party hereby irrevocably waives all rights to a jury trial in connection
with any dispute under the Agreement. 
 (d)     Continued Performance. Except where clearly prevented by
the area in dispute, the Parties shall continue performing their obligations under the Agreement while the dispute is being resolved under this Section 10.10 unless and until the dispute is resolved or until the Agreement
is terminated as set forth in the Agreement. 
 Section 10.11 Specific Performance. The Parties agree
that irreparable damage may occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the Parties shall be entitled to seek specific performance of the terms hereof, in addition to any other remedy to
which they are entitled at law or in equity. 
 Section 10.12 Counterparts; Electronic Documents. 

(a)     This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which
together shall be deemed to be one and the same agreement. 
 (b)     A signed copy of this Agreement (including copies
made using scanning technology) delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 [SIGNATURE PAGE FOLLOWS] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 UCYCLYD / HYPERION ASSET PURCHASE AGREEMENT 

Page 44 of 45 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

			
	UCYCLYD PHARMA, INC
	
	 /s/ Richard D. Peterson

	By:	 	Richard D. Peterson
	Title:	 	Executive Vice President, Chief Financial Officer and Treasurer
	
	HYPERION THERAPEUTICS, INC.
	
	 /s/ Donald J. Santel

	By:	 	Donald J. Santel
	Title:	 	President and Chief Executive Officer

 Signing solely for purposes of the following Sections: 4.04, 4.05, 5.01(a), 5.02(a), 5.03(a) 5.04(b), 5.11, 7.02 (as
applied pursuant to 7.02(d)), 8.03 and those other provisions of Article VIII that pertain to Medicis as an indemnifying party, and those provisions of Article X that pertain to a party under the Agreement: 

 

			
	MEDICIS PHARMACEUTICAL CORPORATION
	
	 /s/ Richard D.
Peterson                    

	By:	 	Richard D. Peterson
	Title:	 	Executive Vice President, Chief Financial Officer and Treasurer

  
 UCYCLYD / HYPERION
ASSET PURCHASE AGREEMENT 
 Page 45 of 45 

 SUMMARY OF SCHEDULES AND
EXHIBITS TO THE ASSET PURCHASE AGREEMENT1 

Seller Disclosure Schedule 
  

			
	Schedule 2.01(a)	  	Product Registrations
	Schedule 2.01(c)	  	Assigned HPN-100 Patents
	Schedule 2.01(d)	  	Assigned Product Registrations and Trademarks
	Schedule 2.01(e)	  	Assigned Contracts
	Schedule 2.05(b)	  	Payment Schedule
	Schedule 2.06	  	Audit and Record-Keeping Requirements
	Schedule 4.01(b)	  	Distributor Territories
	Schedule 7.01(c)	  	Press Release announcing the execution of the Asset Purchase Agreement and the Amended and Restated Collaboration Agreement
		
	Exhibit A	  	Bill of Sale
	Exhibit B	  	Assignment and Assumption Agreement
	Exhibit C	  	Technology Assignment Agreement
	Exhibit D	  	Mutual Release Agreement

  

	1 	 Hyperion Therapeutics, Inc. agrees to furnish supplementally a copy of any omitted schedule or exhibit to the
Securities and Exchange Commission upon request.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]